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For in this hope we were saved. But hope that is seen is no hope at all. Who hopes for 
what they already have? But if we hope for what we do not yet have, we wait for it 
patiently. In the same way, the Spirit helps us in our weakness. We do not know what we 
ought to pray for, but the Spirit himself intercedes for us through wordless groans. And 
he who searches our hearts knows the mind of the Spirit, because the Spirit intercedes for 
God’s people in accordance with the will of God. And we know that in all things God 
works for the good of those who love him, who have been called according to his 
purpose. For those God foreknew he also predestined to be conformed to the image of his 
Son, that he might be the firstborn among many brothers and sisters. And those he 
predestined, he also called; those he called, he also justified; those he justified, he also 
glorified.         
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The use of encapsulated cell systems is widespread in the field of Tissue 
Engineering.  They are primarily used to deliver cells that secrete therapeutic molecules.  
More specifically, encapsulated systems have shown promise in the delivery of insulin-
secreting cells or cell clusters to revert diabetes.  Although often overlooked, 
cryopreservation is critical in bringing these constructs from the laboratory to the clinic.  
Two main types of cryopreservation are currently being investigated for the preservation 
of tissue-engineered constructs: conventional freezing and vitrification.  Conventional 
freezing is often used for preserving cell suspensions and uses low concentrations of 
cryoprotective agents (CPAs), slow cooling and rapid warming.  Vitrification, or ice-free 
cryopreservation, utilizes high concentrations of CPAs paired with rapid cooling and 
warming to achieve a vitreous, or glassy, state.  Our overall goal was to determine the 
effects of both types of cryopreservation on the in vitro and in vivo performance of an 
encapsulated cell system, a model tissue-engineered pancreatic substitute.  The specific 
aims in this thesis were (1) to model CPA delivery and removal to encapsulated cells, and 
their effects on cell viability; (2) to characterize in vitro the effects of cryopreservation 
protocols on cell viability and the biomaterial structure and function of a pancreatic 
substitute; (3) to characterize in vivo the effects of cryopreservation on the 
biocompatibility and efficacy of a pancreatic substitute.  This research addresses the 
systematic design of vitrification protocols and how these protocols and conventional 
freezing affect a tissue-engineered construct.  Our results indicate that temperature of 
exposure is the most critical parameter for the proper design of vitrification protocols.  
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Overexposure is another concern as it leads to a decrease in viable cell number.  The use 
of a mathematical model is critical for the design of addition and removal protocols to 
ensure CPA equilibration and minimize CPA exposure.  Results from in vitro studies 
indicate that both vitrification and conventionally frozen perform comparably to fresh.  
However, in vivo studies reveal that vitrification performs worse than both conventionally 
frozen and fresh beads.  With adjustments, it may be possible to improve the performance 
of the vitrified beads.  Nevertheless, for this encapsulated system, conventional freezing 







It is estimated that 23.6 million Americans have Type 1 or Type 2 diabetes 
mellitus although not all of these have been diagnosed (Vijan 2010).  An additional 50 
million Americans are estimated to have impaired fasting glucose and 25% of these will 
develop Type 2 diabetes, likely within the next two and a half years (Stolar 2010).  Type 
1 diabetics require daily exogenous insulin and were previously known as insulin-
dependent diabetics.  Although not all of those diagnosed with Type 2 diabetes currently 
require exogenous insulin, the pathogenesis of this disease indicates the eventual need for 
exogenous insulin for many who are diagnosed.  Exogenous insulin is readily available 
but does not provide the tight glycemic control that is present in a healthy individual.  
The use of exogenous insulin is life-saving for diabetics, but it is not the ideal treatment. 
Currently, whole organ transplantation and transplantation of the insulin-secreting cell 
clusters, islets of Langerhans, are the only treatments that can achieve glycemic control 
mimicking that of a healthy individual.  These two treatments require lifelong 
immunosuppression and are plagued by cell source issues.  Alternatively, the use of 
encapsulation to deliver insulin-secreting cells or cell clusters has shown promise.  The 
physical barrier of encapsulation provides a level of immune protection that allows the 
use of allogeneic and xenogeneic cell sources with reduced immunosuppression.  As this 




The encapsulation and delivery of insulin-secreting cells or cell clusters to treat 
insulin-dependent diabetes appears promising.  However, as is the case with any tissue-
engineered construct, additional obstacles remain before it can achieve widespread 
clinical use.  Due to manufacturing processes, lengthy sterility testing and quality control 
testing, tissue-engineered constructs will need to be successfully preserved.  The 
preservation of these constructs is considered to be critical in providing off-the-shelf 
availability in a clinical setting (Karlsson and Toner 1996; Pancrazio et al. 2007; 
Sambanis 2000).   
Conventional freezing and vitrification are the two main types of cryopreservation 
currently being investigated.  Conventional freezing utilizes low levels of cryoprotective 
agents (CPAs) along with slow cooling and rapid warming.  This method is termed 
conventional freezing because it has commonly been used to preserve cell suspensions in 
laboratory cell banking.  Conventional freezing allows ice formation which occurs 
preferentially in the extracellular space or extracellular matrix (ECM) (Karlsson and 
Toner 1996; Pegg 2010).  Extracellular ice formation may not have a significant effect on 
the preservation of cell suspensions.  However, ice formation has been shown to cause 
damage to the ECM (Agudelo and Iwata 2008; Heng et al. 2004; Mukherjee et al. 2005) 
when used for the preservation of larger tissue-engineered constructs or natural tissues.  
This ice formation may be detrimental to the biomechanical function of the construct 
(Schenke-Layland et al. 2007).  Additionally, ice damage may change the overall 
morphology of the construct which could result in an increased inflammatory response in 
vivo (Bunger et al. 2003; Lanza et al. 1991).   
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Vitrification, or ice-free cryopreservation, utilizes high concentrations of CPAs, rapid 
cooling and rapid warming to eliminate ice formation and achieve a vitreous, or glassy, 
state.  Unfortunately, the use of high concentrations of CPAs also introduces the issues of 
osmotic excursions and CPA cytotoxicity.  Exposing cells to a high concentration (6-8M) 
of CPA in a single step will lead to excessive osmotic excursions which will shrink the 
cell until the electrolyte concentration within the cell is lethal.  Single-step removal of 
such high concentrations of CPAs would also lead to excessive osmotic excursions, 
resulting in cell lysis.  To circumvent this issue, CPA solutions are generally added and 
removed in multiple steps to minimize osmotic excursions.  The high concentration of 
CPAs is itself toxic to cells and so exposure during addition and removal must be 
minimized. 
The use of conventional freezing and vitrification for the preservation of encapsulated 
cell systems has seen mixed results.  Conventional freezing has been successfully used to 
maintain human and porcine islets (Beattie et al. 1997; Stiegler et al. 2006).  The 
encapsulation itself may benefit the outcome as alginate encapsulation of neurospheres 
has been shown to improve the outcome of conventional freezing compared to free 
neurospheres (Malpique et al. 2010).  Alternatively, conventional freezing has been 
shown to damage the alginate matrix (Agudelo and Iwata 2008; Heng et al. 2004; 
Mukherjee et al. 2005) which may be detrimental to the function of the construct.          
Initial studies in our laboratory indicated that systematically designed vitrification 
protocols minimize cell death and maintain the integrity of the alginate bead.  The tissue-
engineered pancreatic substitute used in these studies consisted of a murine insulinoma 
cell line, βTC3 cells, encapsulated in a calcium-alginate/poly-L-lysine/alginate (APA) 
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bead.  Conventionally frozen beads performed worse than vitrified beads in their insulin 
secretory function, although some vitrified groups experienced more cell death than 
conventionally frozen beads (Mukherjee et al. 2005).  The proliferative nature of the cells 
may allow them to rebound from low viability.  Unfortunately, these vitrification studies, 
done by Dr. Mukherjee, required manual manipulation to achieve appropriate cooling and 
warming rates and did not allow for overnight storage.  In order to be more clinically 
relevant and consistent, a mechanical freezer equipped with an isopentane bath was used 
to achieve the necessary cooling and warming rate for further studies.  In this new 
system, the better performing vitrification solution, VS55 consisting of 3.1M dimethyl 
sulfoxide (DMSO) + 2.2M 1,2 propanediol (PD) and 3.1M formamide, was no longer 
consistently vitrifiable.  Another previously used solution, DP6+0.3MS consisting of 3M 
DMSO + 3M PD and 0.3M sucrose, was modified by raising the sucrose concentration to 
0.5M to ensure consistent, successful vitrification.  Additionally, preliminary studies 
indicated that a simpler conventional freezing protocol utilizing 10% DMSO in fully-
supplemented DMEM was comparable or better for the βTC-tet cell line than the 
previous protocol which incorporated mannitol in removal steps.  This new protocol may 
also be a better reflection of general laboratory practices.  The use of the βTC-tet cell line 
replaced the use of the βTC3 cell line.  The βTC-tet cell line has been engineered for 
growth regulation in the presence of tetracycline and has been successfully used in vivo 
(Black et al. 2006).  After these modifications were made, research was initiated to 
determine the effects of cryopreservation, both conventional freezing and vitrification, on 




 In order to gain insight into the design of CPA addition and removal protocols and 
their effect on the success of preservation, the previously published mathematical model 
describing the mass transport through the matrix and cellular membrane (Mukherjee et al. 
2008) was expanded to incorporate heat transport as well as cytotoxicity due to CPA 
exposure.  CHAPTER 3 describes the experimentally determined cytotoxicity kinetics for 
two of the most commonly used CPAs, DMSO and PD for varying exposure times and 
temperatures as well as a range of concentrations.  Supplemental data for these studies 
can be found in the APPENDIX A.  The experimental results were subsequently 
described using a toxicity equation adapted from the field of sterilization.  CHAPTER 4 
utilizes this toxicity equation in the expansion of the mathematical model.  The 
mathematical model was used to gain insight into the design of addition and removal 
protocols for the encapsulated system as well as a more challenging natural tissue, 
articular cartilage.  Matlab® code for the mathematical model is given in APPENDIX B. 
 Simultaneous to the expansion of the mathematical model, research was initiated 
to examine the effects of cryopreservation on the cellular and biomaterial components of 
the tissue-engineered pancreatic substitute as seen in CHAPTER 5.  Designed CPA 
addition and removal protocols for two vitrification solutions, DPS (3M DMSO + 3M PD 
+ 0.5M Sucrose) and P6 (1M DMSO +5M PD + 0.34M polyethylene glycol), were used 
to vitrify APA beads containing βTC-tet cells.  Samples were rapidly cooled to -100°C, 
then more slowly cooled through the glass-transition temperature to -130°C.  For 
conventional freezing, beads were exposed to 10% DMSO in supplemented medium for 
10 minutes before being slowly cooled to -80°C and then plunged in liquid nitrogen 
(LN2).  Preserved samples were stored overnight before warming.  The cellular 
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component was assessed for viable cell number as well as insulin secretory function.  The 
biomaterial component was assessed for integrity by mechanical testing and permeability 
studies.  Overall morphology and matrix integrity were assessed histologically. 
 After in vitro assessment, two in vivo studies were undertaken to determine the 
effects of cryopreservation on the in vivo inflammatory response to the beads and the 
overall in vivo efficacy of the beads in reverting an induced diabetic mouse model.  The 
sub-therapeutic and therapeutic in vivo studies are described in CHAPTER 6.  For the 
sub-therapeutic study, healthy mice were implanted with a small volume of fresh, 
vitrified or conventionally frozen APA beads.  Mice were sacrificed on days 2, 7 and 14 
and the explants were assessed for secretory function, host-cell attachment and overall 
morphology.  Short-term therapeutic studies were carried out in streptozotocin-induced 
diabetic mice.  Diabetic mice were implanted with a therapeutic volume of fresh, vitrified 
or conventionally frozen APA beads.  Mice were sacrificed upon implant failure or at two 
weeks, whichever came first.  Explants were assessed in the same way for both 
therapeutic and sub-therapeutic studies.   
 All of the aforementioned chapters contain the motivation, experimental methods, 
results and discussion.  General information on insulin-dependent diabetes and 
cryopreservation are reviewed in CHAPTER 2.  CHAPTER 7 discusses conclusions and 
future research directions.   
In summary, this thesis determined the effects of a rationally designed 
vitrification protocol and a conventional freezing protocol on the in vitro and in vivo 
performance of an encapsulated system.  A mathematical model, expanded to incorporate 
heat transfer and CPA cytotoxicity, was used to design CPA addition and removal 
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protocols.  This mathematical model could be easily adjusted for use with a variety of 
natural tissues or tissue-engineered constructs.  Experimental studies on the in vitro and 
in vivo performance of conventionally frozen or vitrified APA beads were carried out.  
Previous studies in this area have utilized a wide variety of techniques and solutions with 
varying success.  Although many of these previous studies indicated successful 
preservation, it remained difficult to ascertain which method of preservation would be 
preferable for a specific system.  This thesis presents one of the first systematic 
comparisons of the two main types of cryopreservation, conventional freezing and 
vitrification, and their effects on the cellular and biomaterial components and in vivo 
efficacy of a tissue-engineered pancreatic substitute.  The results presented in this thesis 
indicate that while vitrification may be better for some tissue-engineered constructs, this 
encapsulated system can be successfully preserved by conventional freezing.  The tissue-
engineered pancreatic substitute is an encapsulated cell system, making these results 






2.1 Diabetes Mellitus and Treatment Options 
Diabetes currently affects approximately 23.6 million Americans (CDC 2007).  
Although many of the patients diagnosed with diabetes do not use exogenous insulin, 
27% of those diagnosed require exogenous insulin.  Diabetics may be diagnosed with 
Type 1 or Type 2 Diabetes.  The two main types are discussed below. 
2.1.1 Type 1 Diabetes Mellitus 
Type 1 Diabetes Mellitus (T1DM) is an autoimmune genetic disease that 
normally presents during childhood.  Although the molecular mechanism is not entirely 
understood, aberrant antigen presentation has been implicated (Todd 2010).  As the 
disease progresses, the insulin-secreting β-cell mass decreases.  This leads to 
compromised insulin secretory capacity.  Patients diagnosed with T1DM depend upon 
exogenous insulin to maintain normal glycemic levels and are considered to be insulin-
dependent.  The incidence of this and other autoimmune diseases is on the rise which 
indicates that unknown environmental factors may also play a role in T1DM (Todd 
2010).  Temporal variations in the disease development within genetically susceptible 
members of the same family indicate that unknown environmental cues may trigger the 
autoimmune response that causes T1DM (Csorba et al. 2010).  Currently, T1DM 
accounts for 5-10% of the diagnosed cases of diabetes in America, according to the CDC 
(National Diabetes Fact Sheet 2007). 
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2.1.2 Type 2 Diabetes Mellitus 
Otherwise known as adult-onset diabetes, Type 2 diabetes mellitus (T2DM) is 
generally associated with obesity and a sedentary lifestyle.  Specific environmental 
factors and genetic predisposition determine a patient’s risk for T2DM (McCarthy 2010) 
although environmental factors appear to play a larger role in the pathogenesis of T2DM 
relative to T1DM.  Type 2 Diabetes manifests as both insulin resistance and decreased 
insulin secretion.  Although the exact mechanisms remain unclear, several deficiencies 
are well documented.  The skeletal muscle consumes most of the circulating glucose in 
the blood of a healthy individual.  Decreased insulin-stimulated glucose uptake of 
skeletal muscle has been implicated as one of the main causes of impaired insulin 
activation, or insulin resistance (Choi and Kim 2010).  Insulin resistance eventually 
causes a decline in β-cell mass and function.  Significant efforts are still being made to 
better understand the pathogenesis of T2DM.  Unfortunately, due to the high incidence of 
obesity in those diagnosed with Type 2 Diabetes, it is difficult to ascertain what 
biochemical cues may cause the progression toward T2DM and what may be a 
consequence of the disease (Tripathy and Chavez 2010).  Nevertheless, the pathogenesis 
of T2DM generally leads to the need for exogenous insulin.  Insulin-dependent diabetes 
(IDD) is on the rise, so it is critical to not only consider its treatment but also the 
complications that often accompany it. 
2.1.3 Current Treatment: Diet, Exercise & Medication 
If diagnosed early enough, the progression of T2DM can usually be slowed 
through better nutrition and increased exercise (Russell-Minda et al. 2009).  Additionally, 
patients are asked to monitor their blood glucose daily so that their physician can 
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determine how far the disease has progressed.  When diet and exercise are insufficient to 
maintain appropriate glycemic levels, oral medications such as Metformin are added to 
the patient’s regimen (Vijan 2010).  Unfortunately, most Type 2 diabetics will eventually 
require the use of exogenous insulin as their disease progresses. 
2.1.4 Current Treatment: Exogenous Insulin 
The administration of exogenous insulin is critical for those with IDD, including 
those with T1DM and some with T2DM.  This often requires the use of multiple 
injections or an insulin pump.  An insulin pump delivers insulin continuously in response 
to input blood plasma glucose levels.  These pumps are capable of calculating dosage and 
varying the profile and duration of the insulin administered.  Evidence suggests that the 
use of an insulin pump is superior to multiple daily injections (Alsaleh et al. 2010).  This 
may be particularly true for Type 1 diabetics who are generally diagnosed at a young age 
and are particularly prone to a fear of injections (Frid et al. 2010).  Due to the high cost of 
insulin pumps, generally $4000-$5000, many diabetics rely on multiple daily injections.  
Unfortunately, studies focused on Type 2 diabetics indicate that only 35.8% of patients 
achieve their recommended glycemic control levels (Stolar 2010).   
2.1.5 Current Treatment: Transplantation 
Whole organ pancreas transplantation is currently the only proven way to achieve 
long-term insulin independence.  Unfortunately, the limited availability makes pancreas 
transplantation an option for very few.  Additionally, pancreas recipients will require 
lifelong immunosuppression to minimize the risk of rejection.  Due to the risks of 
immunosuppression, pancreas transplantation is generally only done in conjunction with 
another organ, such as kidney or liver (Lam et al. 2010).  The alternative of islet 
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transplantation appeared to be very promising after the publication of the Edmonton 
protocol which utilized low-level immunosuppression to increase the success of 
transplanted islets (Shapiro et al. 2000).  By 2005, there were 66 patients in the 
Edmonton series who had received transplants.  Most achieved insulin independence for 
some amount of time, but the median time for these patients to require insulin therapy 
again was just 15 months (Robertson 2010).  The implantation of islets is also currently 
plagued with other issues, such as tissue availability, standardization of pancreas 
digestion and loss of islet function over time (Langer 2010).   
2.1.6 Complications 
The incidence of the secondary complications of diabetes generally increases with 
the duration of disease.  On average, patients diagnosed before the age of 35 lose around 
26 years of life due to secondary complications (Stolar 2010).  The most prevalent 
complication is cardiovascular disease which was responsible for approximately 50% of 
the deaths caused by complications of T2DM in 2010 (Zoungas and Patel 2010).  
Additional complications include retinopathy which can result in loss of vision, 
nephropathy which can result in renal failure and neuropathy which generally includes 
loss of sensation in extremities as well as foot ulcers.  Although the mechanisms that 
cause these complications are varied, evidence indicates that hyperglycemia plays a role 
(Nathan 1993).  Utilizing intensive insulin therapy may lower the chances of 
experiencing these complications but also increases the possibility of hypoglycemic 
episodes (Tesfaye and Seaquist 2010).  Hypoglycemia is of particular concern for those 
who require exogenous insulin because the body’s usual response to hypoglycemia, a 
decrease in insulin secretion, is rendered ineffective.            
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2.2 Tissue-Engineered Pancreatic Substitute 
2.2.1 Cell Source 
One of the most critical issues in developing alternative, tissue engineering 
strategies for the treatment of IDD is the cell source.  In recent years, several sources 
have come to the forefront for consideration in a tissue-engineered pancreatic substitute.  
The most prominent of these is the use of islets.  Significant work has been done in this 
area since the Edmonton protocol was published (Shapiro and Lakey 2000).  Due to the 
limited supply of cadaveric donor tissue, efforts have focused on the use of xenogeneic 
islets, most often porcine.  Porcine insulin is very similar to human insulin and the use of 
pigs could provide a ready supply of islets.  Research has been done to investigate the use 
of adult, neonatal and fetal porcine islets but due to the xenogeneic nature of the islets, 
some amount of immunosuppression or immune protection is generally used.  Efforts in 
this field have yielded multiple porcine to non-human primate transplantations with 
varied success (Hering and Walawalkar 2009).  The use of encapsulated islets, which 
exhibit a level of immune protection due to the physical barrier provided by the 
encapsulation, has emerged as one of the more promising technologies.  Encapsulation 
can be done in conjunction with immunosuppression for improved performance (Safley 
et al. 2005).  Several challenges remain before islets will be clinically relevant.  Islets are 
somewhat fragile and difficult to isolate consistently (Ricordi et al. 1986) and are 
particularly prone to hypoxia-induced damage (de Groot et al. 2004).  Additionally, the 
number of islets required by most clinical patients is approximately 10,000 islet 
equivalents/kg (Emamaullee and Shapiro 2007), making the necessary implant volume, 
and therefore the implant site, an issue. 
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Several other cell sources are currently being considered.  Stem cells, either 
embryonic or induced pluripotent, have been investigated to replace the insulin-secreting 
β-cells present in a healthy individual.  Induced pluripotent stem cell-derived β-like cells 
have recently been used to demonstrate glucose-responsive insulin secretion and have 
successfully reverted diabetes in diabetic mice for up to four months (Alipio et al. 2010).  
The use of embryonic stem cells is farther off due to the difficulty and low efficiency of 
differentiation (Guo and Hebrok 2009).  Unfortunately, in both of these cases, the risk of 
teratoma, or tumor, formation remains, as well as concerns about the immune response to 
the cells.   
Genetically engineered non-β cells have also shown promise.  In theory, these 
cells could be harvested from the patient, expanded, genetically engineered and then 
implanted in the same patient.  Most efforts have centered on the use of cells that already 
exhibit glucose-responsive behavior.  Enteroendocrine cells have been used because their 
native function is to secrete incretin hormones, which help regulate insulin secretion.  
Studies done with these cells have shown insulin secretion (Bara and Sambanis 2009) 
although not enough to revert diabetes in a diabetic mouse model (Bara et al. 2009).  
Other groups have seen success using both enteroendocrine cells (Han et al. 2007) and 
genetically engineered adipocytes (Ito et al. 2005).  Native hepatocytes are also sensitive 
to glucose.  Hepatic cells have been successfully genetically engineered to release insulin 
in a glucose-responsive manner (Kozlowski et al. 2007; Thule et al. 2000).  These 
technologies will still require significant work before they become viable treatment 
options for IDD.           
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The most simple cell source used in the laboratory is proliferating cell lines, 
usually derived from mice, rats or humans.  Many of the cell lines that exist are not 
responsive to glucose stimulation in the physiological range or require additives to be 
responsive (Skelin et al. 2010).  Work done in Dr. Efrat’s laboratory at Albert Einstein 
College utilized transgenic mice to develop the βTC cell lines.  Although initial cell lines 
developed by this group were not responsive to glucose stimulation (Efrat et al. 1988), 
later cell lines have been shown to have normal glucose responsiveness for up to 60 
passages.  Additionally, the βTC-tet cell line allows growth regulation with cell growth 
arrested in the presence of tetracycline (Fleischer et al. 1998).  These cells have been 
widely studied and well characterized by several different groups (Black et al. 2006; 
Cheng et al. 2006; Simpson et al. 2005).  Due to their robust nature and insulin secretion 
characteristics, these cells are particularly useful in the laboratory setting. 
2.2.2 Microencapsulation 
The encapsulation of cells or cell clusters is promising and has been applied to 
treat anemia, dwarfism, kidney and liver failure as well as pituitary and central nervous 
system deficiencies (de Vos et al. 2006).  Microencapsulation is particularly promising 
due to the short diffusion lengths of beads which are comparable to the maximum 
diffusion length of oxygen (Mueller-Klieser et al. 1986).  For encapsulated systems with 
a semi-permeable membrane, the overall risk of implant failure is also minimized 
because each microsphere has an individual membrane rather than the entire implant 
relying on a single membrane (Soon-Shiong 1999). 
Calcium alginate/poly-L-lysine/alginate (APA) beads, as shown in Figure 2.1, 
have been most widely used for encapsulation (Dusseault et al. 2005), in part due to the 
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mild conditions of encapsulation (Gugerli et al. 2002).  Alginate is derived from seaweed 
and is composed of mannuronic (m) and guluronic acid (g) residues.  High-mannuronic 
acid alginates have been shown to bind more effectively with poly-L-lysine (PLL) (de 
Groot et al. 2004), but are not as stiff as high-guluronic acid alginates. This is due to the 
accepted mechanism of cross-linking, known as the egg-box model, shown in Figure 2.2 
(Grant et al. 1973).  Both high-m and high-g alginates have been studied and 
characterized for the encapsulation of β-cells (Constantinidis et al. 1999; Stabler et al. 
2001).  The use of PLL in conjunction with the alginate does not affect β-cell growth 
(Benson et al. 1997) and has been shown to play a significant role in the stability of 
alginate beads (de Groot et al. 2004).  The alginate used for encapsulation must also be 














Concerns about APA beads are primarily due to the PLL layer. The PLL layer 
serves as a semi-permeable membrane that is meant to allow nutrients and oxygen in as 
well as therapeutic molecules, such as insulin, and waste products out.  Although it does 
not allow immune cells, such as macrophages in, it does allow smaller signaling 
molecules such as TNF and IL-1β to pass through (Kulseng et al. 1997).  These 
molecules play a role in the host reaction to the beads (Robitaille et al. 2005).  
Additionally, PLL is considered to be inflammatory (de Vos et al. 2006; Ponce et al. 
2006).  This has been noted by several groups (Safley et al. 2008; Strand et al. 2001) and 
may be due to incomplete coverage by the second alginate layer (de Groot et al. 2004; 
Juste et al. 2005).  
In response to these concerns, many different materials have been suggested.  
Barium has been used as an alternative to calcium because barium cross-links more 
strongly with alginate (Zimmermann et al. 2005). Barium alginate has been used with 
some success either alone (Safley et al. 2008) or in conjunction with a poly-L-lysine layer 
Figure 2.2 Egg-box model. Solid circles represent calcium ions positioned 
between “G-blocks” of consecutive guluronic acid residues.  “M-blocks” of 
consecutive mannuronic acid residues represented by curves. 
Adapted from Simpson, et al. 2004.
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(Li et al. 2006a).  Concerns still remain due to the known toxicity of barium (de Vos et al. 
2006).  Other materials that have been used with limited success include polyethylene 
glycol (Weber et al. 2006), polyanions based on poly(methyl vinyl ether-alt-maleic acid) 
(Gardner et al. 2010), agarose (Kumachev et al. 2011) and alginate with vinyl monomers 
(Wang et al. 2005) or methacrylates (Jeon et al. 2009) for polymerization. 
2.2.3 Macroencapsulation 
Macroencapsulation has also been investigated for the delivery of secreting cells 
or cell clusters.  The larger dimension of these constructs makes the diffusion of oxygen a 
concern.  Two geometries have commonly been used in an attempt to circumvent this 
issue: hollow fiber and disc.  Studies have shown that correctly designed hollow fibers 
can provide sufficient oxygenation to maintain cells and even allow growth and 
propagation (Cornolti et al. 2009; Hoesli et al. 2009).  The design of these devices is 
critical to their success.  Increased surface area to volume will lead to increased function 
and growth of cells.  The cell density also plays a significant role in the function of the 
cells.  Higher cell densities have been found to significantly increase insulin secretion due 
to cell-cell signaling (La Flamme et al. 2007).  In vivo studies have had varied results 
with reports of success in reverting diabetes in mice when using hollow fibers (Delaunay 
et al. 1998) and less success when comparing the hollow fiber and disc geometry to 
microencapsulated spheres (Yang et al. 1994).  A few new technologies may help to 
overcome the current limitations of macroencapsulation.  Fibrin ribbons can be 
incorporated in polyethylene glycol scaffolds to increase vascularization (Mason and 
Mahoney 2010).  Cell sheet engineering using chondrocytes has also been used recently 
to deliver insulin-secreting cells.  Unfortunately, this study did not see long-term 
18 
 
maintenance of insulin secretion (Lee et al. 2008).  Designing a geometry that will 
accommodate the number of cells necessary for a larger animal remains problematic.   
2.3 Cryopreservation 
The need for preservation of tissues and tissue-engineered constructs is widely 
recognized (Karlsson and Toner 1996; Sambanis 2000).  Several main types of 
preservation exist: desiccation, hypothermia and cryopreservation.  Desiccation, or 
freeze-drying, is usually done for pharmaceuticals and proteins.  This process causes an 
increase in solute concentration due to drying that allows the formation of a vitreous, or 
glassy, state.  Although desiccation can provide long-term storage, most research has 
focused on the process of drying and ignored the issue of rehydration.  This method may 
one day be viable for more than pharmaceuticals and proteins but significant work 
regarding rehydration remains to be done.  Additionally, it is not clear that desiccation 
would adequately preserve three-dimensional constructs, especially hydrogels which are 
commonly used as biomaterials.   
Hypothermia and cryopreservation both take advantage of the relationship 
between temperature and cell metabolism.  Most enzymes exhibit a two-fold decrease in 
activity for every 10°C decrease in temperature (Belzer and Southard 1988).  Therefore, a 
decrease from 37°C to 0°C will result in enzyme activity that is 8% of the original 
activity.  Hypothermic storage occurs around 4°C and significantly slows the metabolism 
of cells.  These cells still require nutrients and oxygen to survive despite their depressed 
metabolism.  Hypothermic perfusion preservation can provide the necessary oxygen, but 
also introduces the possibility of pressure-driven shear stress damage (Fuller and Lee 
2007).  Unfortunately, the length of storage possible with hypothermic storage is only on 
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the order of hours to days (Van Buskirk et al. 2004).  Due to this, hypothermic storage is 
primarily used for tissues that have not yet been successfully cryopreserved.  
Cryopreservation utilizes cryoprotective agents (CPAs) to replace a portion of water 
within the cell or construct.  Cryopreserved constructs and tissues are held at 
temperatures ranging from -80 to -196°C and the storage time can extend from months to 
years (Van Buskirk et al. 2004).  At sufficiently low temperatures, all rotational and 
translational molecular motion ceases and cells achieve a state of stasis (Brockbank et al. 
2003).  Although there are difficulties associated with the cryopreservation of tissues or 
tissue-engineered constructs, this method of preservation currently appears to be the most 
promising. 
2.3.1 Cryoprotective Agents (CPAs) 
The definition of a CPA is functional.  A CPA is classified as such because 
experiments have shown that it will yield higher post-thaw survival than could be 
achieved without it (Fuller 2004).  Commonly, CPAs are divided into two categories: 
permeating and non-permeating.  Permeating CPAs, such as dimethyl sulfoxide (DMSO) 
or propanediol (PD), have low molecular weights and can pass through the cell 
membrane (Karlsson and Toner 1996).  These serve to displace water within the cell and 
protect against intracellular ice formation (Brockbank and Taylor 2007).  Polymers and 
sugars are often used as non-permeating CPAs.  Due to their high molecular weight, they 
cannot pass through the cell membrane.  The most commonly used non-permeating CPAs 
are trehalose, sucrose, polyethylene glycol (PEG) and polyvinylpyrrolidone.  These 
solutes serve different purposes depending on the type of cryopreservation.  As they 
cannot permeate into the cells, they can serve to draw more water out of the cells or they 
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may be used to affect the extracellular solution properties (Fuller 2004).  Although CPAs 
are used to improve the overall outcome of cryopreservation, they can also be toxic to 
cells.  Toxicity is a function of the temperature of exposure, time of exposure, CPA 
identity and CPA concentration (Elmoazzen et al. 2007) and will be discussed further in 
the context of the two main types of cryopreservation: conventional freezing and 
vitrification. 
2.3.2 Conventional Freezing 
Conventional freezing utilizes low concentrations of CPAs which are generally 
coupled with slow cooling and rapid warming.  This approach has been most successfully 
used to preserve cell suspensions.  The most commonly used CPA in conventional 
freezing is DMSO. 
2.3.2.1 Basic Operating Procedures 
Two main types of damage can occur to cells during conventional freezing: 
solution effects and intracellular ice formation.  Both of these phenomena occur during 
the cooling step and are determined by the rate of cooling, as seen in Figure 2.3.  During 
cooling, ice forms preferentially in the extracellular space or matrix (Li and Liu 2010; 
Pegg 2010) and causes a decrease in the concentration of water outside of the cells.  
Extracellular ice does not incorporate solutes and so the concentration of the CPA and 
other solutes outside of the cell increases (Szarko et al. 2010).  This creates a 
concentration gradient across the cell membrane which generally causes water to move 
out of the cell.  If the rate of cooling is too slow, too much water will exit the cell and the 
intracellular electrolyte concentration will increase.  This can cause cell death and is 
denoted “Solution Effects” in Figure 2.3.  Alternatively, if the rate of cooling is too rapid, 
21 
 
the rate of extracellular ice formation will exceed the rate of water permeating out of the 
cell.  As the sample is cooled, the temperature will eventually be low enough to cause the 
cell membrane to be virtually impermeable (Karlsson and Toner 1996).  At some point, 
the cell will become supercooled and intracellular ice will form, denoted “Intracellular 
Ice Formation” in Figure 2.3.  Any amount of intracellular ice formation (IIF) is lethal to 
most cell types.  Optimally, the cooling rate should be sufficient to allow some 
intracellular water to escape so that, as the cell is cooled, the intracellular environment 
will become highly viscous and achieve a vitreous, or glassy, state that will not allow ice 
formation.  The use of CPAs in conventional freezing is primarily to replace water within 
the cell.  This decreases the chances of IIF and the CPA acts as a solvent to reduce the 





Figure 2.3 Survival curve indicating mechanisms of cell death 
during cooling in conventional freezing.   
(Karlsson and Toner 1996) 
 




The warming step is also important to the outcome of conventional freezing.  
Generally, the warming rate should be equivalent to or faster than the cooling rate used.  
If the rate is equivalent, the cell will undergo the same osmotic excursions that were 
experienced upon cooling.  Faster warming allows more rapid melting of ice.  However, 
if the rate of warming for a slowly cooled sample occurs too rapidly, excessive osmotic 
excursions may occur as the cell is rehydrated.  
2.3.2.2 Challenges 
Although the use of conventional freezing is sufficient for the cryopreservation of 
cell suspensions, the occurrence of extracellular ice may be detrimental to tissues or 
constructs.  A prominent cryobiology investigator, Dr. David Pegg, recently stated, “It 
seems to be inescapable that the formation of ice, whether intracellular or extracellular, in 
tissues and organs is severely damaging (Pegg 2010).”  This is particularly true for 
tissues that primarily serve a mechanical purpose (Schenke-Layland et al. 2007).  
Additionally, the occurrence of ice is generally random and heterogeneous (Brockbank et 
al. 2003).  Impurities or particulates serve as nucleation sites and contribute to the 
random nature of ice formation.  Some proponents of conventional freezing have 
recommended the seeding of ice at a particular temperature to eliminate the random 
nature of ice formation.  Even in this situation, ice may be damaging.  
2.3.3 Vitrification 
Vitrification utilizes high concentrations of CPAs, rapid cooling and rapid 
warming to achieve ice-free cryopreservation.  Although vitrification generally occurs 
intracellularly in conventional freezing, the term vitrification refers to an ice-free state 
throughout the system.   
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2.3.3.1 Operating Procedures 
Ice formation is usually governed by thermodynamics.  However, in vitrification, 
ice nucleation becomes governed by kinetics.  The high concentrations of CPAs slow the 
formation of ice crystals and rapid cooling brings the sample to the glass-transition 
temperature, Tg, before ice crystals can form.  At Tg, the solution is so viscous that 
molecular diffusion stops.  This stops the growth of any ice nuclei that may have formed.  
Although called ice-free cryopreservation, vitrification is defined as having a total 
crystallized fraction of less than 10E-6 (Karlsson and Toner 1996).  This can be 
determined using thermal analysis, such as differential scanning calorimetry, but is often 
confirmed by macroscopic observation (Weiss et al. 2010). 
To achieve the vitrified state, a sample must be cooled very quickly.  The critical 
cooling rate is the rate at which ice formation will be suppressed.  It varies depending on 
CPA or CPA cocktail used and the concentration of solutes present in the solution.  The 
addition of non-permeating CPAs is especially useful for vitrification and can increase 
the stability of the glassy state or decrease the critical cooling rate.  Warming is also 
critical as devitrification and recrystallization are common problems.  It is very likely that 
a vitreous state will still contain ice nuclei.  If the warming rate isn’t fast enough, ice 
crystals will form, denoted as devitrification, and grow, denoted as recrystallization.  This 
formation of ice will occur very rapidly and may be more detrimental to cells than the ice 
formation that occurs in conventional freezing.  The critical warming rate is the rate 
above which there is insufficient time for crystallization to occur before the system 
reaches the melting point (Brockbank et al. 2003).  The CPAs or CPA cocktails that are 
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used to vitrify dictate the critical cooling and warming rates necessary to successfully 
achieve vitrification.   
2.3.3.2 Challenges 
Although consistently achieving the critical cooling and warming rates is 
important for successful vitrification, these rates can be manipulated to within 
experimentally achievable parameters by using different or higher concentrations of 
CPAs.  The more difficult challenge is incorporating the higher concentrations of CPAs 
without damaging the cells.  Two types of damage generally occur when using such high 
concentrations of CPAs: excessive osmotic excursions and cytotoxicity.     
In order to maintain osmotic excursions within a tolerable range, high 
concentrations of CPAs must be added in a step-wise manner.  This is particularly true 
for constructs where mass transfer through the construct must also be included.  
Appropriate CPA addition and removal protocols can be designed using mathematical 
modeling (Mukherjee et al. 2008).  These protocols will maintain cells within tolerable 
cellular volumes during the addition and removal procedures. 
The issue of CPA cytotoxicity specifically arises due to the high concentrations 
necessary to achieve vitrification.  The low concentrations of CPAs used for conventional 
freezing are usually in the range of 10-20%.  Cells do not experience significant toxicity 
at these levels (Heng et al. 2004; Judas et al. 2007; Stiegler et al. 2006).  CPA toxicity is 
dependent upon time and temperature of exposure as well as CPA identity and 
concentration.  Cytotoxicity has been noted as being the limiting factor for successful 
cryopreservation (Fahy 2010).  For the preservation of larger constructs or tissues, mass 
transfer limitations may require longer exposure to CPAs.  In response to this, novel 
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CPAs or CPA carrier solutions have been proposed (Matsumura et al. 2010; Wusteman et 
al. 2008a).  Additionally, the idea of CPA Toxicity Neutralization has led to the use of 
CPA cocktails to achieve the necessary concentrations (Fahy 2010).  Non-permeating 
solutes are also being used by some to replace permeating solutes (Grondin et al. 2009; 
Katenz et al. 2007; Petrenko et al. 2008) as toxicity has been shown to depend more 
heavily on permeating than non-permeating CPAs (Fahy et al. 2004).  In spite of this 
work, CPA toxicity continues to be a challenge in the vitrification of cells, constructs and 
tissues.          
2.4 Cryopreservation of Tissue-Engineered Constructs & Tissues 
While the cryopreservation of cell suspensions has been shown to be relatively 
simple, this is not the case for larger systems.  More specifically, the preservation of 
natural tissues or tissue-engineered constructs is much more complex.  Although the field 
of Tissue Engineering is relatively new with the flagship journal being launched in 1995, 
significant work has already been done to investigate the preservation of tissue-
engineered constructs.  Microencapsulation is of particular interest for delivery of 
secreting cells or cell clusters.  Cryopreservation of an encapsulated cell system has 
yielded highly variable results.  Conventional freezing has been successful for 
maintaining encapsulated islets (Schneider and Klein 2011; Stiegler et al. 2006) and 
myoblasts (Murua et al. 2009) as well as their in vivo function.  Studies have also shown 
that the success of conventional freezing is improved by the alginate encapsulation 
(Malpique et al. 2010).  However, other groups have reported that conventional freezing 
leads to damage in the matrix of an encapsulated system (Agudelo and Iwata 2008; Hang 
et al. 2010; Heng et al. 2004; Mukherjee et al. 2005).  Encapsulated cells and islets have 
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also been successfully preserved using vitrification, although none have compared the 
performance of the two methods within the context of in vivo efficacy (Agudelo et al. 
2009; Wu et al. 2007).  Additionally, alginate encapsulation appears to improve the 
success of vitrification (Zhang et al. 2010).   
Ice damage to the extracellular matrix is clearly detrimental for constructs that 
serve a biomechanical function (Schenke-Layland et al. 2007).  Vitrification has been 
shown to maintain the viscoelastic properties of human vascular grafts better than 
conventional freezing (Thakrar et al. 2006).  Other studies have shown that the ice 
formation that occurs during the conventional freezing of tissue-engineered blood vessels 
significantly decreases the tissue’s ability to contract (Dahl et al. 2006).  Vitrification 
may also be preferable for adherent cells.  There is evidence that suggests that 
conventional freezing downregulates the β1 integrin that is critical to attachment for 
hepatocytes (Terry et al. 2007).   
2.5 Mathematical Modeling of Cryopreservation Processes 
Significant amounts of modeling efforts have focused on the understanding of 
different processes in cryopreservation.  Many of these reflect the challenges associated 
with the CPAs themselves and predicting their behavior.  These range from the synthesis 
of phase diagrams (Han et al. 2010; Kleinhans and Mazur 2007) and mixing of CPAs 
(Kyrychenko and Dyubko 2008) to the prediction of critical cooling rates for different 
CPAs (Fan et al. 2007).  Several studies have sought to understand the process of 
conventional freezing (Cui et al. 2002), or more specifically the issue of intracellular ice 
formation (Li and Liu 2010; Ross-Rodriguez et al. 2010).  However, few have attempted 
to use simulations to gain insight into the vitrification process.  In order to minimize the 
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CPA cytotoxicity experienced by cells, it is critical to address the addition and removal 
protocols.  Cell membrane permeability is an important component of this and has been 
reviewed in the context of cryobiology by Kleinhans (Kleinhans 1998).  More recently, 
this has been incorporated into a model describing the mass transfer and membrane 
permeation of CPAs for the vitrification of articular cartilage (Mukherjee et al. 2008).  
Mathematical models such as these allow for systematic design of protocols that 
minimize cell death due to excessive osmotic excursions. 
2.6 Animal Model of Diabetes 
There are many different animal models, although most in vivo studies begin with 
a small animal model.  For the study of diabetes, this can be one of several commonly 
used models.  Previous studies using βTC-tet cells, a murine insulinoma cell line, have 
shown success in an allogeneic host (Black et al. 2006).  Therefore, it is desirable, when 
comparing methods of preservation for a tissue-engineered pancreatic substitute, to focus 
on a mouse model.  Two main models have been used throughout literature to investigate 
diabetes: a streptozotocin (stz)-induced mouse model and a non-obese diabetic (NOD) 
mouse model.  Streptozotocin is an alkylating drug that specifically targets and destroys 
the insulin-secreting β cells in the mouse.  As stz is metabolized, it produces reactive 
oxygen species.  Beta cells are particularly susceptible to oxidative changes.  Oxidative 
stress has also been implicated in the mechanism of β-cell death in NOD mice (Morimoto 
et al. 2005).  Rather than being induced, the NOD mouse exhibits a spontaneous 
occurrence of diabetes with 90% of female and 60% of male mice achieving a diabetic 
state between 12-30 weeks of age.  This strain of mouse was developed by inbreeding 
and selecting for hyperglycemia.  Due to this, the NOD mouse may also have specific 
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genes and phenotypes that may not be relevant to diabetes (Rees and Alcolado 2005).  
Additionally, NOD mice may not reflect human IDD as they can survive for weeks 




CYTOTOXICITY EFFECTS OF CRYOPROTECTANTS AS 
SINGLE-COMPONENT AND COCKTAIL VITRIFICATION 
SOLUTIONS1 
Cryoprotectant (CPA) cytotoxicity constitutes a challenge in developing 
cryopreservation protocols, specifically in vitrification where high CPA concentrations 
are necessary to achieve the ice-free, vitreous state.  Few cytotoxicity studies have 
investigated vitrification-relevant concentrations of CPAs, and the benefits and 
disadvantages of cocktail solutions and of incorporating non-permeating solutes have not 
been fully evaluated.  In this study, we address these issues by determining the 
cytotoxicity kinetics for dimethylsulfoxide (DMSO) and 1,2-propanediol (PD) on 
alginate-encapsulated βTC-tet mouse insulinomas for a range of concentrations and 
temperatures.  Cytotoxicity kinetics were also determined for two cocktails, DPS (3M 
DMSO + 3M PD + 0.5M sucrose) and P6 (1M DMSO + 5M PD + 0.34 M polyethylene 
glycol with M.W. of 400).  PD was found to be more cytotoxic than DMSO at higher 
concentrations and temperatures.  This was reflected in P6 being more cytotoxic at room 
temperature than P6 at 4oC or DPS at either temperature.  Addition of non-permeating 
solutes increased the cytotoxicity of cocktails.  Furthermore, results indicate that CPA 
cytotoxicity may not be additive and that combining CPAs may increase cytotoxicity 
synergistically.  Finally, when comparing cytotoxic effects towards encapsulated HepG2 
and βTC-tet cells, and towards βTC-tet cells in capsules and in monolayers, CPAs appear 
more cytotoxic towards cells with higher metabolic activity.  The incorporation of these 
                                                 
1 This work is in press: Lawson, Ahmad & Sambanis (2011).Cryobiology. 10.1016/j.cryobiol.2011.01.012  
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results in the rational design of CPA addition/removal processes in vitrification is 
discussed. 
3.1 Introduction 
Within the field of Cryobiology, much work has been done to determine the 
cytotoxic effects of the cryoprotectant agents (CPAs) necessary for preservation.  The 
cytotoxicity of CPAs has been shown to increase with time, temperature and 
concentration (Wang et al. 2007b).  Cytotoxicity is especially critical for vitrification, 
which requires much higher concentrations of CPAs.  Recently, vitrification has been 
touted by some to be the most promising method of preservation for tissues (Fahy et al. 
2006) as well as tissue-engineered constructs (Kuleshova et al. 2007; Yin et al. 2009) due 
to the need to minimize or eliminate ice formation during preservation.  Very few of the 
cytotoxicity studies available achieve the high concentrations of cryoprotectants 
necessary for successful vitrification (Wang et al. 2007b; Wusteman et al. 2002).  To 
improve the vitrification process, several investigators have chosen to use cocktail 
solutions combining CPAs to achieve the necessary concentrations.  These cocktails have 
gained widespread use for two reasons.  The combination of different permeating and 
non-permeating CPAs has been shown to decrease the total concentration necessary to 
achieve successful vitrification (Petrenko et al. 2008; Sutton 1992).  Also, the addition of 
non-permeating CPAs may improve the viability and function of the cells or tissues that 
are preserved (Beattie et al. 1997; Kuleshova et al. 1999; Li et al. 2006b).  Some studies 
have focused on determining the predictability of vitrification (Shaw et al. 1997) and 
vitrification solution toxicity (Fahy et al. 2006; Fahy et al. 2004).  However, few of these 
studies have directly compared the cocktail solutions to their individual CPA components 
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to determine if cytotoxicity may be additive or have synergistic effects to either reduce or 
increase cytotoxicity.  Most that have investigated this have focused on the addition of 
additives that do not contribute to the overall glass-forming ability of the solution, such 
as amides (Fahy 2010; Fahy et al. 1987).   
Additional questions that remain on the use of CPAs in cryopreservation include 
variations on CPA cytotoxicity towards different cell types or even the same cell in 
different types of culture.  Evidence for these differences can be seen in a review of 
studies which range from the preservation of embryos (Kuleshova et al. 1999; Mukaida et 
al. 1998) to tissues (Elmoazzen et al. 2007; Wang et al. 2007b) or cells (Wusteman et al. 
2002; Wusteman et al. 2008b).  To our knowledge, although cytotoxicity studies have 
been carried out for many of these, no studies have investigated differences in 
cytotoxicity towards cells cultured in monolayers and cells in tissue constructs or a tissue 
itself.      
In this study, we address these critical issues concerning the cytotoxicity of CPAs.  
Alginate-encapsulated mouse insulinoma βTC-tet cells were chosen for the majority of 
the experiments due to their use as a pancreatic substitute (Gross et al. 2007; Simpson et 
al. 2005).  Cytotoxicity measurements were performed in a systematic way so as to 
investigate the effects of temperature, concentration and exposure time.  Initial studies 
focused on single-component CPAs applied at concentrations of 2M to 6M in order to be 
relevant for both conventional freezing and vitrification.  The cytotoxicity of cocktail 
CPAs with and without non-permeating solutes was compared to single-component 
CPAs.  To address the effects of culturing method on cytotoxicity, the cytotoxic effects of 
CPAs towards βTC-tet cells in monolayers and in capsules were evaluated and compared.  
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Lastly, variations of CPA cytotoxicity towards different cell types were studied by 
comparing CPA effects on encapsulated HepG2 cells and βTC-tet insulinomas.  
Conclusions regarding fundamental issues of CPA cytotoxicity and the use of such 
systematic studies in designing optimized cryopreservation protocols are discussed.   
3.2 Materials and Methods 
3.2.1 Cell Culture 
Mouse insulinoma βTC-tet cells were obtained from Dr. Efrat, Albert Einstein 
College of Medicine, Bronx, NY (Fleischer et al. 1998).  Monolayer cultures were 
initiated from frozen stocks and propagated in T-flasks in complete growth medium 
consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, St. Louis, 
MO) supplemented with 10% fetal bovine serum (Gemini Bioproducts, West 
Sacramento, CA), 1 % L-glutamine (Mediatech, Inc., Manassas, VA) and 1 % 
penicillin/streptomycin (Mediatech, Inc.).  Monolayer human liver carcinoma HepG2 
cells (American Type Culture Collection, Manassas, VA) were cultured in DMEM 
(Cellgro by Mediatech, Inc.) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin as above.  Cells were incubated in a humidified incubator at 37°C 
and 5% CO2 and were split at a ratio of 1:5 (βTC-tet) or 1:10 (HepG2) when 90% 
confluent.  Experiments were performed with βTC-tet cells of passage 38-44 and with 
HepG2 cells of passage 18-23.  For monolayer studies, βTC-tet cells were plated at a 
density of 500,000 cells/well in 24-well cell-culture treated plates (Corning Inc., Corning, 
NY).  The cells were cultured as above for two days before cytotoxicity studies were 
performed.   
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3.2.2 Alginate Encapsulation 
Encapsulation of βTC-tet and HepG2 cells was carried out using previously 
published protocols (Stabler et al. 2001), briefly as follows.  Cells were detached from 
monolayer cultures by trypsinization (0.25% Trypsin-EDTA, Mediatech Cellgro) and 
suspended at a density of 3.0x107 cells/ml of 2% sodium alginate (Pronova Ultra Pure 
LVM alginate NovaMatrix of FMC BioPolymer AS, Norway).   An electrostatic droplet 
generator (Nisco Engineering AG, Zurich, Switzerland) was used to generate droplets 
which fell into a well-stirred 1.1% CaCl2 bath, forming beads of gel containing entrapped 
cells.  Complete growth medium was used to wash and store the beads.  Beads were 
cultured overnight in a non-tissue culture treated T-flask on a rocker plate in a 37°C and 
5% CO2, humidified incubator.  For cytotoxicity studies, beads were transferred to a 100 
µm cell strainer (Becton-Dickinson, Franklin Lakes, NJ) and exposed to CPA solutions in 
a non-treated 6-well plates (Corning).  Beads were agitated throughout CPA addition and 
removal except for the final addition step where they were agitated for 4 minutes 
regardless of incubation time.                     
3.2.3 CPA Solutions  
Solutions for cytotoxicity studies were prepared using a concentrated and 
modified version of the EuroCollins carrier solution containing 174.76 g/L dextrose, 5.6 
g/L KCl, 4.2 g/L NaHCO3 and 8.2 g/L NaCl.  This concentrated EuroCollins solution was 
diluted in the final solution volume at a ratio of 1:5.  The cocktail solutions were DP6 
(3M DMSO + 3M PD), DPS (3M DMSO + 3M PD + 0.5M Sucrose), P6 (1M DMSO + 
5M PD + 0.34M polyethylene glycol with M.W. 400) and 5/1 (1M DMSO + 5M PD).  
All chemicals were purchased from Sigma-Aldrich except sucrose and NaHCO3 (Fisher).  
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DP6 was compared to the complete solution, DPS, and 5/1 compared to the complete 
solution, P6, in order to investigate the effect of the non-permeating solutes.  CPAs were 
added in a step-wise fashion.  Protocols for addition and removal were designed using a 
previously established model (Mukherjee et al. 2007).  Cells were incubated in the final 
solution for different times to determine the kinetics of cytotoxicity. Incubation times for 
other addition and removal steps remained constant for all solutions.  The 
addition/removal protocols for cocktails and high concentration single-component CPA 
solutions are shown in Table 3.1.  All addition steps were carried out at the indicated 
temperature (4°C or room temperature) and all removal steps were carried out at room 
temperature.  Room temperature was 25°C ± 1°C, while 4°C was achieved by keeping 
solutions in an ice/water bath.   
 
 
Table 3.1. Addition and removal protocols for 6M PD, 6M DMSO, DPS, PEG400, DP6 
and 5/1. Sucrose is denoted S. Lower concentration single component CPAs were added 
and removed in the same manner: 2M was added in one step (A2) and removed in one 
step (R4), 4M was added in two steps (A2, A3) and removed in two steps (R3, R4).  
*Incubation in final addition step was changed to determine cytotoxicity kinetics. 
 
 
Solution 6M PD 6M DMSO DPS P6 DP6 5/1 Time 
(min) (M) PD/S  DMSO/S  DMSO/PD/S  DMSO/PD/PEG  DMSO/PD/S DMSO/PD/S  
A1 -- -- -- 0.25/1/0 -- -- 4 
A2 2/0 2/0 1/1/0.15 0.5/2/0.1 1/1/0 0.33/1.67/0 4 
A3 4/0 4/0 2/2/0.3 0.75/3.5/0.2 2/2/0 0.67/3.33/0 4 
A4 6/0 6/0 3/3/0.5 1/5/0.3384 3/3/0 1/5/0 15* 
R1 -- -- 2.25/2.25/0.3 0.75/4/0.2 -- -- 2 
R2 4/0.5 4/0.6 1.5/1.5/0.2 0.5/2/0.2 2/2/0.5 0.67/3.33/0.5 2 
R3 2/0.25 2/0.35 0.75/0.75/0.1 0.25/1/0 1/1/0.25 0.33/1.67/0.3 2 
R4 0/0 0/0 0/0/0 0/0/0 0/0/0 0/0/0 4 
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3.2.4 Metabolic Activity and Viability 
To determine the metabolic activity of cells, 100 µL alginate beads or a cell 
monolayer were incubated with a solution of alamarBlue™ consisting of 100 µL 
alamarBlue™ and 1 mL complete growth medium in a 12 well plate for 3 hours 
(encapsulated βTC-tet cells), 4 hours (monolayer βTC-tet cells) or 1.5 hours 
(encapsulated HepG2 cells) in a 37°C and 5% CO2, humidified incubator.  Incubation 
times for alamarBlue™ were varied due to different cell number (encapsulated βTC-tet 
cells vs. monolayer βTC-tet cells) or metabolic activity of the cells (βTC-tet cells vs. 
HepG2 cells).  With the selected incubation times, all assays fell within range wherein 
fluorescence was proportional to metabolic activity.  A control consisting of 100 µL of 
alamarBlue™ and 1 mL medium was incubated for the same length of time. After this 
incubation, 100 µL supernatant from each well was transferred to a black 96 well plate 
and the fluorescence read using a SPECTRAMAX Gemini Fluorescent plate reader 
(Molecular Devices, Sunnyvale, CA) using an excitation wavelength of 544 nm and an 
emission wavelength of 590 nm.  The data obtained from treated encapsulated cells using 
this assay were normalized to the data from untreated beads.  For monolayers, the 
untreated control was subjected to the same number of washes as the test groups but was 
washed with complete growth medium.  This was done to account for any detachment 
due simply to washing.   
Cell viability was assessed using the dye exclusion stain Trypan Blue (0.4% 
Sigma).  Beads were dissolved using 2% sodium citrate (Fisher).  The resulting cell 
suspension was added to Trypan Blue in a 1:1 ratio and stained cells with compromised 
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membranes and non-stained cells were counted.  Trypan blue-linked viability, henceforth 
referred to simply as viability, was normalized to the data from untreated beads. 
3.2.5 Statistical Analysis 
Although regression analysis is often used when considering time as a variable, 
the time points investigated were discrete and the data were collected from independent 
test groups.  Therefore, statistical calculations were performed using a one-way ANOVA 
and Tukey’s test to determine differences due to exposure time, temperature and 
concentration of CPA.  For the comparison of single-component CPAs to cocktails, test 
groups were only compared to other test groups at the same temperature and exposure 
time.  For comparisons of βTC-tet vs. HepG2 cells and of encapsulated cells vs. 
monolayers, statistical differences were evaluated only between cell type or culture 
method keeping all other variables the same.  A p value of less than 0.05 was considered 
to indicate statistical difference.     
3.3 Results and Discussion 
CPA cytotoxicity is of particular concern in vitrification, which, to achieve the 
vitreous state, requires much higher CPA concentrations than conventional freezing.  The 
chemical identity of the CPA used, the exposure time, temperature and concentration all 
play a role in the survival of cells during addition and removal procedures.  Single-
component CPAs and CPA cocktails were investigated to determine the role that these 
parameters play in the overall cytotoxicity of the solution.  These studies were carried out 
with encapsulated βTC-tet cells.  The same system was used to address the question of 
additivity of cytotoxicity in cocktail solutions relative to single-component CPAs.  To 
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determine the effect of the mode of cell culture on CPA cytotoxicity, experiments were 
carried out with βTC-tet cells cultured in monolayers and in capsules.  Finally, 
cytotoxicity studies were performed with encapsulated βTC-tet cells and encapsulated 
HepG2 cells to investigate the extent to which cytotoxic effects vary between cell types.  
Results are described and discussed below.   
3.3.1 Single-Component CPAs 
Results on the viability of encapsulated βTC-tet cells exposed to DMSO or PD for 
various times, at different concentrations, and at two temperatures, are shown in Figures 
3.1 and 3.2.  Pairwise comparisons were done for all groups and the results are shown in 






Figure 3.1. Cell viability vs. time for DMSO for 2M ( ), 4M ( ) and 6M ( ) at 
4°C or room temperature (empty) for encapsulated βTC-tet cells.  Cell viability 


























Table 3.2. Pairwise comparisons of single-component cytotoxicity kinetics.  p<0.05 for 
corresponding letters (e.g. p<0.05 when comparing 2M and 6M DMSO at 30 minutes at 





Incubation at 4°C Incubation at Room Temperature 
4 min 10 min 15 min 30 min 4 min 10 min 15 min 30 min 
2M DMSO - - - - - - - A 
4M DMSO - - - - - - - - 
6M DMSO - -  - - - - - A 
                  
2M PD - - - S L J G D,E 
4M PD - - - T M K H D,F    





Figure 3.2. Cell viability vs. time for PD for 2M ( ), 4M ( ) and 6M ( ) at 4°C or 
room temperature (empty) for encapsulated βTC-tet cells. Cell viability normalized to untreated 
control. Error bars not shown for clarity. Statistical significance shown in Table 2,  n=3.   
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As expected, cell viability generally decreased with an increase in time, 
temperature or concentration for either CPA.  Viability decreased only slightly when cells 
were exposed to DMSO with the only significant decrease occurring at room temperature 
as concentration was increased from 2M to 6M with an incubation time of 30 minutes.  
The relatively high viabilities remaining after incubation in 6M DMSO at shorter 
incubation times also indicate that cell death due to osmotic excursions has been 
minimized.  PD resulted in lower cell viabilities than DMSO at higher concentrations and 
temperature.  Although cell viability did not decrease significantly over a change in 
temperature or time for incubation in 2M or 4M PD, incubation in 6M PD caused a 
significantly higher loss of viability, which increased with time and temperature.  This is 
an indication that temperature control is much more important for PD than for DMSO.  
These results corroborate several previous studies which have shown that PD is more 
cytotoxic (Tsai et al. 2008; Wusteman et al. 2008b).  It has been shown that temperature 
control during CPA addition and removal is critical for maintaining cell viability during 
vitrification (Pegg et al. 2006; Wang et al. 2007a).  However, the importance of 
temperature control may vary with the identity of CPAs, alone or in cocktails.  To our 
knowledge, these data are the first to show that PD cytotoxicity is more dependent on 
temperature than that of DMSO. 
The metabolically active cell number measured by alamarBlue™ exhibited the 
same trends although it was consistently lower than viability and appeared to be more 
susceptible to the CPA cytotoxicity as concentration, time or temperature increased 
(results not shown).  There are several possible reasons for this difference, the most likely 
being that exposure to CPAs lowers the metabolism of cells before compromising the 
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integrity of cell membranes.  Indeed, studies with human hepatocytes (Stephenne et al. 
2007) and other cell types (He and Woods 2004) indicate that cryopreservation reduces 
cellular metabolism, although it is unclear if this occurred because of the CPA exposure, 
the cooling/warming process, or both, as these studies investigated the aggregate effect.  
Another possibility for the difference in the assays is that exposure to the CPAs may 
activate apoptotic pathways, as demonstrated in porcine embryos (Rajaei et al. 2005). 
This may become evident in metabolic activity assays before causing a loss in membrane 
integrity.  Additionally, the processes of vitrification (Rahimi et al. 2009) and 
conventional freezing (Baust et al. 2000; Heng et al. 2006) have both been shown to 
activate apoptosis, although again these studies evaluated the aggregate CPA 
addition/removal and cooling/warming effects.  In our studies, direct apoptosis 
measurements were not performed.  In several of the experiments, encapsulated cells 
subjected to CPA addition/removal were cultured for another day and the viability 
measured.  This indirect measure indicated that no significant apoptosis occurred 
(APPENDIX).  We chose to present Trypan blue-linked viability, rather than total 
metabolic activity, for the majority of the figures, as this is a more direct measure of 
cellular necrosis.  Additionally, a depression in cellular metabolism may be reversible 
while the loss of membrane integrity necessary for Trypan blue to enter the cell is not.     
3.3.2 CPA Cocktails 
The toxicity kinetics for DPS and P6 were studied and compared (Figure 3.3).  
The toxicity of P6 was comparable to DPS at 4°C; however, P6 exhibited a much higher 
increase in toxicity as temperature was increased.  In this case, statistical comparisons 
were made between P6 at room temperature and DPS at both temperatures as well as P6 
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at 4°C.  Encapsulated cells exposed to P6 at room temperature had a statistically lower 
viability at each time point relative to P6 at 4°C or DPS at either temperature.  These 
results indicate that temperature control is much more important for P6 than for DPS; 
they are also compatible with the single-component cytotoxicity results, as the 
concentration of PD is higher in P6 than DPS, resulting in the viability being more 
temperature-dependent for the P6 cocktail.  On the other hand, the loss of cell viability 
caused by CPA cocktails was higher than the sum of cell viability loss caused by the pure 
CPAs at the concentrations found in the cocktail, with the latter obtained or estimated 
from Figures 3.1 and 3.2.  Therefore, further experiments were carried out to directly 
compare the cytotoxicity of the single components to those of the cocktails without the 
non-permeating CPAs (DP6 and 5/1) and finally, to those of the full cocktails (DPS and 
P6).   These studies were performed at a single incubation time (15 minutes) for the 










Results from these studies are shown in Figures 3.4 and 3.5.  These figures also  
show the “cumulative viability” values calculated as shown below using average 
viabilities at the corresponding temperature and concentration of each CPA in the 
cocktail (e.g., 3M PD and 3M DMSO viabilities used to determine “cumulative viability” 
for DP6).  These values have no error bars and statistical significance is not indicated.   
)viability1()viability1(1 viabilityCumulative 21 CPACPA −−−−=  
It should also be noted that, in our hands, 6M PD, 6M DMSO, 5/1 and DP6 are not 
vitrifiable (as evidenced by macroscopic observation) and in order to consistently achieve 
Figure 3.3. Cell viability vs. time for P6 ( ) and DPS ( ) at 4°C or room temperature 
(empty) for encapsulated βTC-tet cells.  Cell viability normalized to untreated control.  
Error bars indicate standard deviations, n=3.  #, † indicate p<0.05 when comparing 
groups.  Additionally, p<0.05 when comparing P6 at RT to all other groups at each time 
point (not indicated for clarity).   
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vitrification, non-permeating solutes need to be added.  Addition of non-permeating 
solutes may allow for a reduction in the concentration of permeating CPA necessary to 
achieve vitrification (Kuleshova et al. 1999; Sutton 1992) and may inhibit ice formation 
during vitrification (Wang et al. 2009).  Currently, non-permeating CPAs are considered 
to have little effect on or be beneficial for the overall solution cytotoxicity (Katenz et al. 
2007; Petrenko et al. 2008; Rodrigues et al. 2008) and may stabilize cell membranes 
(Rudolph and Crowe 1985).  However, those results were obtained with low 
concentrations of CPAs which may not be significantly toxic to cells.  Our results show 
that the viabilities of cells exposed to complete cocktails were lower than those of cells 
exposed to incomplete cocktails, consisting only of the permeating CPAs, and the latter 
were closer to the cumulative viabilities.  Although the introduction of a non-permeating 
solute may improve the consistency of solution vitrification, it resulted in an increase in 
cytotoxicity, the only exception being 5/1 relative to P6 at 4°C (Figure 3.5).  A possible 
reason for this is that the addition of non-permeating CPAs results in an increase in the 
intracellular concentrations of permeating CPAs, as also predicted by membrane 
permeability models (Kleinhans 1998).  Overall, it is important that the possibility of 
significantly increasing cytotoxicity be considered when adding non-permeating CPAs to 











Figure 3.4. Cell viability for 6M DMSO, 6M PD, DP6 and DPS compared to 
“cumulative viability” for an incubation period of 15 minutes for encapsulated βTC-tet 
cells.  Cell viability normalized to untreated control.  Error bars indicate standard 
deviations, no error bars for cumulative viability, n=3.  * indicates p<0.05  
Figure 3.5. Cell viability for 6M DMSO, 6M PD, 5/1 and P6 compared to “cumulative 
viability” for an incubation period of 15 minutes for encapsulated βTC-tet cells.  Cell 
viability normalized to untreated control.  Error bars indicate standard deviations, no error 
bars for cumulative viability, n=3.  * indicates p<0.05  
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Some interesting comments can also be made in comparing single-component 
cytotoxicity to that of cocktails.  The less cytotoxic CPA, DMSO at 6M concentration, 
resulted in comparable or higher viabilities relative to cocktail solutions at either 
temperature.  This was also the case for 6M PD at 4°C.  However, at room temperature 
6M PD performed worse than DP6 and DPS and was comparable to 5/1, as expected 
given that 5/1 is mostly PD.  However, addition of the non-permeating PEG in forming 
P6 significantly increased the cytotoxicity of the latter relative to 6M PD and 5/1.  These 
results suggest that the presence of PD at a high concentration in a cocktail affects the 
temperature dependence significantly.   
Notably, P6 and 5/1 performed differently at the two temperatures, with P6 being 
less cytotoxic than 5/1 at 4°C but more cytotoxic at room temperature.  The increase in 
cytotoxicity at room temperature is likely due to the decreased intracellular water content 
as discussed above.  The difference at 4°C might be due to the protective effect of non-
permeating solutes cited in several publications (Katenz et al. 2007; Petrenko et al. 2008; 
Rodrigues et al. 2008; Rudolph and Crowe 1985).  These results therefore suggest that 
the protective effect of non-permeating CPAs is present at low temperatures, but it is 
outweighed by the negative osmotic effects at higher temperatures.   
As seen in Figures 3.4 and 3.5, the cumulative viabilities appear higher than those 
obtained with the incomplete cocktails.  This suggests that CPA cocktail cytotoxicity may 






3.3.3 Comparison of Culturing Method  
Figure 3.6 shows the normalized number of metabolically active cells, measured 
by alamarBlue™ for βTC-tet cells in suspension within an alginate matrix and in 
monolayers exposed to different CPAs at 4°C and room temperature for 15 min.  It 
appears that the cells in a monolayer fare better than encapsulated cells at low 
temperatures and concentrations while they experience more cytotoxicity at higher CPA 







Figure 3.6. Viable cell number for 3M DMSO, 3M PD and DP6 for monolayer βTC-tet 
cells (stripes) compared to encapsulated βTC-tet cells (solids) for an incubation period 
of 15 minutes.  Viable cell number determined by alamarBlue™, normalized to 
untreated control.  Error bars indicate standard deviations, n=3.  *, # indicates p<0.05.  
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There are several differences between the two systems that may explain these 
results.  The most obvious difference is that there is a short period of time necessary for 
diffusion of the CPAs towards the center of the alginate bead.  Previous studies 
(Mukherjee 2008) investigated the diffusion of different CPAs into and out of alginate 
beads at room temperature.  Those results, also temperature-corrected for diffusion at 
4°C, indicate that equilibration is essentially reached within two to three minutes at either 
temperature, which is negligible given the exposure time of 15 minutes.  Hence, 
diffusional resistance is an unlikely cause of the observed difference.  Additionally, the 
cytotoxicity experienced by the encapsulated cells is not consistently lower due to a 
shorter exposure time.  Another difference between the two systems is the culture itself.  
βTC-tet cells encapsulated in alginate are suspended whereas those in a monolayer are 
adhered to the tissue culture surface.  This difference is the most likely cause for the 
results as studies investigating the metabolism of a similar cell line, βTC3 murine 
insulinomas, have shown that the metabolism of monolayers is significantly higher than 
encapsulated cells (Simpson et al. 2006).  This increase in metabolism would cause an 
increase in the cytotoxic effects at room temperature and higher concentrations.  At the 
lower temperature, the effects of higher metabolism are tempered as metabolism is 
significantly depressed (Belzer 1988).  These effects would also be less noticeable at 
lower concentrations where the CPAs are less cytotoxic.  The reason for the differences 
at lower temperatures is less clear.  It might be that the results showing that monolayers 
experience less cytotoxicity when exposed to a lower concentration of CPAs at a lower 
temperature is actually a reflection of the control group that was used for normalization.  
The control monolayer group was subjected to the maximum number of washes, 
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corresponding to the number of washes used in the addition and removal for DP6, albeit 
with supplemented DMEM.  These extra washes may have caused some detachment of 
living cells which then resulted in artificially high normalized viability.  This difference 
would not be seen at room temperature where the metabolism, and possibly attachment, 
is higher.  These data indicate that monolayer cytotoxicity studies may not be directly 
applicable to the same cells in suspension, seeded in a construct, or present in a natural 
tissue.   
3.3.4 Comparison of Cell Type 
  The cytotoxic effects of DMSO, PD and DP6 on encapsulated βTC-tet and 
HepG2 cells were determined for an incubation period of 15 minutes at 4°C and room 
temperature.  Results on the normalized cell viability measured by Trypan Blue are 
shown in Figure 3.7.  The cytotoxicity of the single-components is very similar between 
the two cell types.  However, the cocktail solution DP6 had a much higher cytotoxicity 
towards HepG2 than βTC-tet cells at room temperature.  This is likely due to the 
difference in metabolism and the rate of cell growth between the two cell lines.  βTC-tet 
cells encapsulated in 2% LVM alginate double in approximately two weeks (Simpson et 
al. 2005) while HepG2s encapsulated in 1% LVM alginate triple in ten days (Chin et al. 
2008).  Despite the small differences in alginate concentration, it is expected that the 
HepG2 cells are more metabolically active than βTC-tet cells.  This is similar to what was 
observed when comparing monolayers and encapsulated cells and indicates that 








Our studies determined the cytotoxicity kinetics on encapsulated βTC-tet cells of 
two commonly used CPAs, DMSO and PD, at different concentrations and two 
temperatures.  Studies were extended to investigate the additivity of CPA cytotoxicity in 
cocktail solutions.  Results generally agree with the literature but allow insight into the 
importance of temperature control and the use of CPA cocktails.  Although it may be 
beneficial to add non-permeating solutes to cocktails to improve their ability to vitrify, 
this addition may not be as innocuous as previously thought.  The importance of 
temperature control varies between CPAs and CPA cocktails and is more critical for cells 
with higher metabolism, either due to cell type or culturing method.   
Figure 3.7. Cell viability for 3M DMSO, 3M PD and DP6 for encapsulated βTC-tet cells 
(solids) compared to encapsulated HepG2 cells (stripes) for an incubation period of 15 
minutes.  Cell viability normalized to untreated control.  Error bars indicate standard 




MATHEMATICAL MODELING OF CRYOPROTECTANT 
ADDITION AND REMOVAL FOR THE CRYOPRESERVATION OF 
ENGINEERED OR NATURAL TISSUES 
 
Long-term storage of natural tissues or tissue-engineered constructs is critical to 
allow off-the-shelf availability.  Vitrification is a method of cryopreservation that 
eliminates ice formation, which may be detrimental to the function of the tissue or 
construct.  In order to achieve the vitreous, or glassy, state, high concentrations of CPAs 
must be added and later removed.  Such high concentrations of CPAs may be deleterious 
to cells as the CPAs are cytotoxic and single-step addition or removal will result in 
excessive osmotic excursions and cell death.  A previously described mathematical model 
accounting for the mass transfer of CPAs through the sample matrix and cell membrane 
was expanded to incorporate heat transfer and CPA cytotoxicity.  Simulations were 
performed for two systems, an encapsulated system of insulin-secreting cells and articular 
cartilage, each with different transport properties, geometry and size.  Both cytotoxicity 
and mass transfer are highly dependent upon temperature, with increased temperature 
allowing more rapid mass transfer but also causing an increase in cytotoxicity.  The 
effects of temperature are exacerbated for articular cartilage, which has a larger 
dimension and slower mass transport through the matrix.  Simulations indicate that 
addition and removal at 4°C is preferable to 25°C, as cell death is higher at the latter 
temperature due to the increased cytotoxicity in spite of the faster mass transport.  
Additionally, the model indicates that less cytotoxic CPAs, especially at high 
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temperature, would significantly improve the cryopreservation outcome.  Overall, the 
mathematical model allows the design of addition and removal protocols that ensure CPA 
equilibration throughout the sample while still minimizing CPA exposure and 
maximizing cell survival. 
4.1 Introduction 
 Significant progress has been made in the field of Tissue Engineering to develop 
and design novel constructs for the repair, replacement or regeneration of certain tissues 
or organs.  However, cryopreservation technologies are often overlooked until a construct 
is very close to being clinically available.  The preservation of these constructs during 
manufacturing processes and transport is critical in bringing these constructs to off-the-
shelf, clinical use (Karlsson and Toner 1996; Sambanis 2000).  The need for preservation 
also extends to natural tissues which are in limited supply.  Cryopreservation may be 
relatively simple for cells in suspension, but the addition of a three dimensional matrix, as 
in a construct or natural tissue, introduces resistance to heat and mass transport (Karlsson 
and Toner 1996).  Therefore, cryopreservation of tissue-engineered constructs or natural 
tissues is rarely straight-forward and often requires significant experimental work to 
achieve success.  Ice formation is also a critical issue as it has been shown to be 
detrimental to the mechanical properties of both tissue-engineered constructs (Dahl et al. 
2006) and natural tissues (Thakrar et al. 2006).  Vitrification, or ice-free cryopreservation 
appears to be the most promising method of preservation (Kuleshova et al. 2007).  
Vitrification requires high concentrations of cryoprotective agents (CPAs) and rapid 
cooling and warming to achieve a vitreous, or glassy, state.  This method eliminates the 
problem of ice formation both within the cell and in the extracellular matrix (Brockbank 
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et al. 2003).  Generally, the high concentrations of CPAs in vitrification are achieved 
using a CPA cocktail solution which is added and removed using multi-step protocols to 
minimize cellular osmotic excursions.  Samples are rapidly cooled and stored in the 
vitreous state before warming and eventual use. 
A significant amount of theoretical work has been done to better understand 
cryopreservation.  Many of the previous studies have focused on the understanding of the 
cooling and warming of the sample during conventional freezing. More specifically, 
these efforts cover important issues such as intracellular ice formation (Li and Liu 2010; 
Ross-Rodriguez et al. 2010), solute interactions (Kyrychenko and Dyubko 2008), effects 
of temperature on cell membrane function (Dragomir and Pausescu 1974) and synthetic 
phase diagrams (Han et al. 2010).  While theoretical studies are important in gaining 
fundamental understanding, very little work has been done to investigate the methods of 
vitrification.  Vitrification requires rapid cooling and warming, but these rates are 
primarily dictated by the critical cooling and warming rates necessary for the solution to 
achieve a glassy state.  There is therefore little room for improvement.  Little theoretical 
work has been done to address the other critical issue of vitrification, which is the 
addition and removal of CPAs and their effect on cells, constructs or natural tissues.  A 
review of current vitrification literature reveals different CPAs and CPA cocktails being 
used to varying effect.  Without better understanding of the addition and removal 
protocol, the preservation of tissue-engineered constructs or natural tissues will remain 
difficult.  A successful protocol will achieve full equilibration of the CPA or CPA 
cocktail throughout the sample to ensure successful vitrification, while minimizing 
osmotic excursions and CPA-induced cytotoxicity; the latter is dependent on the CPA 
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identity and concentration as well as the exposure time and temperature (Lawson et al. 
2011).   
To address all of these complexities, a previously published mathematical model 
(Mukherjee et al. 2008) of mass transfer through the extracellular matrix and cellular 
membrane was expanded to incorporate heat transfer and CPA cytotoxicity.  This model 
describes the CPA addition followed by immediate removal and does not consider the 
rapid cooling, storage or warming that would occur during vitrification.  Addition and 
removal protocols were designed to maintain osmotic excursions of the cells within 
tolerable limits and achieve CPA equilibrium throughout the entire construct.  The 
temperature and duration of addition and removal steps were varied to determine their 
effects on cytotoxicity.  In order to gain additional insight, these simulations were carried 
out for two systems with different transport properties, geometry and size.  The first 
system modeled was an encapsulated cell system of spherical geometry that is small in 
size (500 µm in diameter) and in which the matrix poses little resistance to mass transfer, 
exhibiting CPA diffusivities equal to approximately 80% of those in water (Mukherjee et 
al. 2007).  The second system was based on articular cartilage of slab geometry, a tissue 
that is notoriously difficult to cryopreserve (Brockbank et al. 2010; Jomha et al. 2002; 
Pegg et al. 2006).  This system had larger dimensions with a clinically relevant overall 
thickness of 2 mm and significantly higher resistance to mass transfer with CPA 
diffusivities close to 30% of those in water (Mukherjee et al. 2008).  These two systems 
were chosen to cover a broad range of tissues and tissue-engineered constructs and the 




4.2 Mathematical Modeling 
A two-compartment mathematical model, previously described for articular 
cartilage, (Mukherjee et al. 2008) was used to characterize the transport of CPAs through 
a hydrogel matrix in spherical geometry (shown in Figure 4.1) and across the cell 
membrane of βTC-tet cells in an encapsulated system.  MATLAB software (MathWorks, 
Natick, MA) was used to couple the two compartments.  Heat transfer and an additional 
equation describing the cytotoxicity kinetics of the βTC-tet cells in the presence of CPAs 
were incorporated into the mathematical model.  The same model structure was also used 
to describe another system: articular cartilage of slab geometry.  The parameters used for 
simulations are shown in Table 4.1.  Chondrocytes, as would be present in articular 
cartilage, were assumed to have the same parameters as βTC-tet cells.  Additionally, the 
dependence of diffusivity and cell permeability on temperature were assumed to follow 



















Table 4.1 Values of model parameters used in this study for mass and heat transfer, 
permeability & cytotoxicity.  Cell permeability parameters and cytotoxicity parameters 
were the same for both cell types.  Water permeability values (Lp) were higher for DMSO 





4.2.1 CPA Transport and Heat Transfer through Matrix 
Effective diffusivities were previously determined for CPAs through 2% calcium-
alginate beads (Mukherjee 2008) and through articular cartilage (Mukherjee et al. 2008).  
These values are given in Table 4.1.  Thermal diffusivity for 2% calcium-alginate beads 
was assumed to be that of water (Bird et al. 2002).  A value from literature for the 
thermal diffusivity of nasal septal cartilage was used to approximate this parameter value 
for articular cartilage.  Although these tissues are different, the thermal properties for 
biological tissues, ranging from skeletal muscle to cardiac tissue, are of the same order of 
magnitude as the approximate thermal diffusivity used in this study for cartilage and it is 
therefore an acceptable approximation (Youn et al. 2000).  The values for both of these 




























Alginate 0.8 1.46E11 -- -- -- -- -- -- -- --
Cartilage 0.3 1.32E5 -- -- -- -- -- -- -- --
DMSO -- -- 6.67E-4 15400 4.73E-2 14100 0.0843 2.0E4 4270 0.08
PD -- -- -- -- 5.81E-2 14600 0.0576 1.2E5 4930 0.17
56 
 
4.2.2 Model Assumptions 
The following assumptions were incorporated in developing the model equations for 
the two types of tissue considered. 
1) No CPA reaction or consumption by the cells or matrix. 
2) Homogenous cell distribution throughout matrix.  This is a good assumption for 
freshly encapsulated cells and immature cartilage which are both relatively 
homogenous (Jadin et al. 2005) 
3) Effective diffusivities and thermal diffusivities are isotropic. 
4) Cell membrane permeability values are only affected by a change in temperature 
and are independent of CPA concentration. 
5) No solute-solute interactions for multi-solute CPA transport across cell membrane 
or in matrix. 
Mass transport through the spherical alginate matrix is described in equation 1 below.  In 
this equation, C = CPA concentration (mol/L), r = radial position (µm) and Deff = 






























         (1) 
The initial and boundary conditions used to solve equation 1 are as follows: 
C(r, t=0) = 0 (no CPA initially present in the matrix)        (2) 
C(r=R, t) = Cexternal (CPA concentration at the bead radius, R, is        (3) 
equal to the external concentration in the bulk liquid,  
i.e. no boundary layer and partition coefficient of 1)  




C  (symmetry at the center of the bead)        (4) 
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Mass transport through the slab geometry of articular cartilage is described in equation 5.  




















eff         (5)  
Heat transfer through the spherical alginate matrix is analogous to mass transport 
as described in equation 1 and is shown in equation 6.  Equation 7 describes heat transfer 
through the slab geometry.  In both equations, α = thermal diffusivity (µm2/s) and T = 













































T α                                         (7)               
  
Initial and boundary conditions for the heat transfer equations (equation 6 & 7) are 
similar to those for mass transport and are shown for the slab geometry (equation 7).   
T(z, t=0) = T0 (articular cartilage at initial temperature, T0)       (8) 
T(z=Z, t) = Texternal (temperature at the slab edge, Z,         (9) 
is equal to the external temperature in the bulk liquid)     




T  (symmetry at the center of the slab)       (10) 
4.2.3 CPA Transport across Cell Membrane 
Parameters for βTC-tet cell membrane permeabilities were previously determined 
(Mukherjee et al. 2007).  A two-parameter formalism with modifications was used to 
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describe solute transport across the cell membrane (Kleinhans 1998).  This is described in 
equations 11 and 12. 
( )iepw MMARTLdt
dV
−−=          (11) 
( )isiesissi MMAPdt
dN
−=          (12) 
Equation 11 describes the water flux through the cell membrane while equation 12 
describes the solute flux.  In these equations, Vw (µm3) is the volume of water inside the 
cell, Lp (µm/s·atm) is the water permeability, A(µm2) is the cell surface area, R 
(µm3·atm/mol·K) is the gas constant, T (K) is the absolute temperature, Me and Mi 
(osmoles/µm3) are the total external and internal osmotic concentrations, respectively, Ps 
(µm/s) is the ith solute permeability, Nsi (osmoles) is the intracellular amount of the ith 
solute and Msie and Msii (osmoles/µm3) are the external and internal osmotic 
concentrations for the ith solute, respectively.  Me and Mi were determined using the 
osmotic virial equation (Eqn 13) and parameters published by Prickett (Prickett et al. 
2010) (shown in Table 4.1).  In equation 13, π is the osmolality of the solution 
(osmole/kg solvent), mi is the molal concentration (moles solute/ kg solvent), and B is the 
osmotic virial coefficient (kg solvent/moles solute).  Osmolality was then converted to 
osmolarity for use in the permeability equations. 
2
iii mBm +=π          (13) 
4.2.4 Cytotoxicity Kinetics 
CPA cytotoxicity is governed by the time and temperature of exposure, CPA 
identity and concentration.  Chemical and thermal cytotoxicity experienced by cells has 
been well characterized in the field of sterilization.  First-order kinetics are often used 
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(shown in equation 14), although these kinetics indicate that the reaction rate constant is 




d−=           (14) 
If the cells within the system are not homogenous, some being more robust than 
others, this should be reflected in the cytotoxicity kinetics.  These states of varying 
resistance to CPA toxicity could be described as a continuous distribution of states in the 
cell population. In order to appropriately reflect this in a system, the subpopulations 
would need to be isolated and the rate constant determined for each.  Alternatively, work 
done by Peleg, et al. suggests that the reaction rate constant could be made dependent on 
time (Peleg and Normand 2004).  This method is shown in equations 15 and 16.  If the 
exponent m is greater than 1, this indicates that cells are progressively weakened due to 
exposure.  Based on previous experimental work (Lawson et al. 2011), the exponent for 
encapsulated βTC-tet cells is less than 1, indicating that cells that are more susceptible to 
cytotoxicity are killed first, leaving more robust cells.  Although this is not a mechanistic 
model, it was chosen for the sake of simplicity.  The reaction rate constant also is 





⎛ ⎞= −⎜ ⎟
⎝ ⎠
          (15) 
( ) 1exp / mdk A E RT t −= −        (16) 
Work done by Char (Char et al. 2010) on sterilization that combines temperature 
and chemical cytotoxicity indicates that the concentration of the chemical affects the 
parameter A, as well as the exponent m.  Therefore, the pre-exponential factor in equation 
16, A, was replaced by bmC, where b is an experimentally fit parameter and C is CPA 
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concentration.  Additionally, E/R is replaced by an experimentally fit parameter, d.  
Finally, the exponent m is replaced by fC where f is an experimentally fit parameter.  
Equation 17 is the result.  This equation was fit to previously published experimental 
cytotoxicity data to determine all parameters (Lawson et al. 2011).   
    ( )( )exp exp /  fC
o
n b C d T t
n
= − ∗ ∗ −        (17)  
In this equation, n is viable cell number, no is initial viable cell number, resulting in a 
survival curve in terms of normalized viable cell number.  Additionally, C is 
concentration in mol/L, T is temperature in Kelvin, t is time in minutes and b, d and f 
have units of L/(mol*min), K, and L/mol, respectively.  Figure 4.2 shows experimental 
data in comparison to the fitted cytotoxicity equation. Parameters were determined by 
least squares fit using Microsoft® Excel® Solver and parameter values are shown in 





Figure 4.2. Comparison of cytotoxicity equation, equation 17, (lines) with 
experimentally determined normalized cell viability (n/n0) (data points) for 2M DMSO 
(black, diamond) or 6M PD (gray, triangle) with addition steps carried out at 25°C (solid) 




4.3.1 Heat Transfer 
Heat transfer was incorporated into the mathematical model for two reasons.  
Previously, the assumption was made that heat transfer would be very rapid compared to 
mass transfer (Mukherjee et al. 2008).  It was necessary to confirm this.  If not, then it 
might have been beneficial to add CPAs as the sample was cooled to minimize 
cytotoxicity.  Figure 4.3 shows the temperature profile for different positions throughout 
the articular cartilage slab in response to step changes in temperature at the edge of the 
slab.  The slab geometry of articular cartilage was chosen as a “worst-case” scenario due 
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to the large dimension and slower thermal diffusivity.  Step changes were simulated from 
37°C (physiological) to 25°C (approximate room temperature), 25°C to 4°C (ice water 
bath) and 4°C to -20°C (freezer).  Even for the largest of these step changes, 4°C to -
20°C, the target temperature is achieved throughout the slab within approximately 10 
seconds.  The time necessary for heat transfer is therefore negligible compared to the 
time necessary for mass transfer which is 40-80 minutes (see Figure 4.6).  Hence, all 





Figure 4.3. Temperature profile at center of slab (z=0), midway through slab (z=0.5mm), 





4.3.2 Mass Transfer through Alginate Bead 
The case of the alginate bead presents little resistance to mass or heat transfer.  To 
be vitrification-relevant, a vitrification solution consisting of dimethyl sulfoxide 
(DMSO), propanediol (PD) and polyethylene glycol was used.  The standard addition and 
removal protocol is given in Table 4.2.  This protocol was designed to ensure that the 
osmotic excursions experienced by the cells within the matrix remained within the 





Table 4.2. Simulated addition and removal protocol for alginate beads.  All removal steps 
were carried out at 25°C.  Addition and removal exposure times were lengthened for 











 Components (M) Time 
(min)  
Temperature 
(°C)  Step  PEG400 PD DMSO 
A1  0  1 0.5 3 4 or 25  
A2  0  2 1 3 4 or 25  
A3  0  4 1 3 4 or 25  
A4  0.3384 5 1 3 4 or 25  
R1  0.2 4 0.75 2 25  
R2  0.2 2 0.5 2 25  
R3  0  1 0.25 2 25  
R4  0  0 0 5 25  
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Figure 4.4A shows results for 4°C or 25°C addition with all removal steps 
occurring at 25°C.  The viable cell number at the edge of the bead is shown because cells 
at the edge are exposed to the CPAs longer than those at the center.  This position serves 
as a “worst-case” scenario although viable cell number varies little (~2%) over the radius 
of the bead due to the small dimension (diameter of 500 µm) and high diffusivity.  These 
results indicate that temperature has a significant effect on the CPA cytotoxicity 
experienced by βTC-tet cells at relatively short timescales.  These short timescales are 
well within the experimental timescales used to determine the cytotoxicity equation 
parameters.  As such, they are a direct reflection of experiment and are interpolated rather 
than extrapolated from experimental data.  Additionally, removal at room temperature 
causes a greater loss in viable cell number (~3%) when addition occurred at 4°C than 
when addition occurred at room temperature (<1%) as shown in Figure 4.4.  This 
difference is relatively small and indicates that the temperature of removal may not be as 
critical for constructs that exhibit rapid mass transfer.  The minimal loss in viable cell 
number that occurs during removal when all exposure is carried out at 25°C indicates that 
the more susceptible cells die during the addition steps leaving more robust cells behind.  
Figure 4.4B shows the concentration of CPA at the center of the bead during addition and 
removal.  Achieving or approaching equilibration of CPAs is critical to the success of 
vitrification.  The temperature of addition and removal significantly affects the amount of 
time necessary to achieve full equilibration.  At a higher temperature, equilibration occurs 
much more quickly, allowing shorter incubation times and decreasing the cell’s exposure 
to CPAs during addition and removal.  Cell viability at the edge of the bead for different 
exposure times is shown in Figure 4.5.  Due to faster mass transport at 25°C, 
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equilibration through the bead occurs within 1.5 minutes/step as opposed to 3 
minutes/step at 4°C.  A direct comparison of the results of properly designed protocols at 
4°C (Figure 4.4A, 3 minutes/step) and at 25°C (Figure 4.5, 1.5 minutes/step) still indicate 
more cell loss at the higher temperature with a resulting normalized viable cell number 
for exposure at 25°C of 89.6%  compared to 93.3%  at 4°C.  Overexposure to CPAs, as 
seen for 3 or 10 minute steps at 25°C (Figure 4.5), further decreases the cell viability in 


















Figure 4.4. A) Normalized viable cell number (n/n0) at edge of bead and B) 
concentration profile for predominant CPA, PD, at center of bead for 4°C (solid gray) 
and 25°C (dashed black) addition and concentration in bulk solution (solid black) for 3 






Figure 4.5. Normalized viable cell number (n/n0) at edge of bead for different exposure 
times at 25°C.  At this temperature, 1.5 min/addition step is sufficient to achieve 











Figure 4.6. A) Concentration profiles of predominant CPA, PD, throughout slab for two 
temperatures and B) total normalized viable cell number (n/n0) in slab for different 







  25°C / 25°C          4°C / 25°C 
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4.3.3 Mass Transfer through Articular Cartilage    
Mass transfer through articular cartilage is hindered due to the dense nature of the 
tissue.  The composition of each addition and removal step for articular cartilage was the 
same as for alginate beads.  To address the mass transfer issues, the duration of the 
addition and removal steps was adjusted.  The duration of all addition and removal steps 
were equal to each other, and this time was adjusted to ensure approximately 90% 
equilibration at the center of the slab by the end of all addition steps.  Concentration 
profiles throughout the slab for exposure at both temperatures are shown in Figure 4.6A.  
The temperature effects on mass transfer are exacerbated for articular cartilage due to the 
reduced diffusivity and increased sample dimension.  Simulations indicate that addition 
steps must be twice as long when carried out at 4°C (80 min/step) than 25°C (40 
min/step).   
Figure 4.6B shows the effects of temperature and overexposure on cytotoxicity by 
comparing three scenarios.  In the first scenario, addition steps occurred at 4°C and 
required 80 min/step to achieve approximately 90% equilibration.  Addition steps for the 
second scenario occurred at 25°C and required only 40 min/step.  These two scenarios 
were compared to overexposure: addition steps carried out at 25°C for 80 min/step.  All 
removal steps were carried out at 25oC and at 40 min/step.  The total normalized viable 
cell number was calculated by integrating the viable cell number over the entire slab 
using the trapezoidal rule.  Results indicate that while overexposure increases cell death, 
temperature also plays a significant role.  Additionally, more cell death is seen during 
removal at 25°C when addition was carried out at a lower temperature (4°C).  These 
effects can be seen more clearly in Figure 4.7, where the normalized viable cell number 
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at the center and edge of the slab is shown for two scenarios: addition and removal at 4°C 
(80 min/step) or addition at 4°C (80 min/step) and removal at 25°C (40 min/step).  These 
results clearly indicate that temperature is critical, even for removal steps.  In the second 
scenario, where addition occurs at 4°C and removal occurs at 25°C, there is a significant 
loss in viable cell number during removal.  The steep decrease in normalized viability at 
the center of the slab during removal at 25oC reflects two distinct phenomena.  The high 
viable cell number present at the beginning of removal indicates the presence of many 
cells that are still quite susceptible to CPA toxicity.  These cells will rapidly die when 
exposed to the higher temperature during removal.  The edge of the slab experiences this 
phenomenon to a lesser extent as the edge of the slab equilibrates with the bulk solution 
concentration almost instantaneously which decreases the CPA concentration and time of 
exposure that occurs during removal.  At the center of the slab, this issue is compounded 
by the slow mass transfer.  Even at the higher temperature, Figure 4.6A clearly shows 
that the center of the slab, as well as the half way inner point, experience prolonged 
exposure to the CPAs during removal when compared to the outer edge of the slab.  This 
is the most likely cause for the lower final viable cell number at the center of the slab as 
compared to the edge.  This prolonged exposure also occurs for removal at 4°C although 
the cytotoxicity at this temperature causes the decrease in viable cell number to be much 
less dramatic.  Overall, removal at 4°C causes an additional viable cell loss of 3.7% at the 
center of the slab compared to 0.6% at the edge the slab.  These simulations indicate that 




Figure 4.7. Normalized viable cell number (n/n0) at center of slab (dashed) or edge of 
slab (solid) for addition steps at 4°C (80 min/step) and removal at 4°C (80 min/step, 
black) or 25°C (40 min/step, gray). 
 
 
The previously published experimental results indicate that DMSO toxicity is 
much less dependent on temperature than PD (Lawson et al. 2011).  Therefore, additional 
simulations were carried out using the cytotoxicity parameters for DMSO rather than the 
combined cytotoxicity that would be expected for the cocktail used in these studies.  
DMSO is slightly less cytotoxic than PD at low temperatures but DMSO cytotoxicity is 
much less sensitive to a change in temperature making it significantly less cytotoxic at 
higher temperatures than PD.  Figure 4.8 compares the normalized viable cell number for 
normal parameters to the “less temperature sensitive” cytotoxicity parameters of DMSO.  
These results indicate that the use of a CPA that exhibits similar cytotoxicity at 4°C and 











exhibits cytotoxicity which significantly increases with temperature.  Even with addition 
and removal occurring at 25°C, 6M DMSO will result in less cell loss throughout the slab 
(92-93.2% viable cell number, Figure 4.8) than the cocktail solution including PD with 
all exposure carried out at 4°C (84-88.7% viable cell number, Figure 4.7).  However, 
DMSO, even at 6M is not vitrifiable, whereas the cocktails that are vitrifiable, such as 






Figure 4.8. Normalized viable cell number (n/n0) at center of slab (dashed) and at edge of 
slab (solid) for 25°C, 40 minute addition and removal steps for DMSO values of 



















The cryopreservation of different tissue-engineered constructs or natural tissues 
presents a significant challenge in bringing them to the clinic.  Due to the wide array of 
tissues, geometries and clinically relevant sizes, it is desirable to be able to design 
addition and removal protocols based on the specific tissue being preserved.  Significant 
work has been done in the area of cryopreservation to better understand the cooling and 
warming process, but little work has been done to better understand and design CPA 
addition and removal protocols.  This study addresses this deficiency.  Although cooling 
and warming rates are dictated by the vitrification solution, the proper design of addition 
and removal protocols can improve the success of the vitrification process.  Three main 
concerns arise when designing addition and removal procedures: osmotic excursions, 
mass transfer and CPA cytotoxicity.  The addition of vitrification-relevant concentrations 
of CPAs in a single step is generally recognized to cause excessive osmotic excursions.  
Previously published work from our laboratory has addressed this issue and validated the 
need to minimize osmotic excursions and maintain them in a tolerable normalized cell 
volume range (Mukherjee et al. 2007).  All simulations carried out in this work maintain 
osmotic excursions within the tolerable range for βTC-tet murine insulinomas.   
The success of vitrification is also contingent upon achieving sufficient mass transfer of 
the vitrifiable solution.  Although recent publications utilize macroscopic observation to 
prove successful vitrification (Weiss et al. 2010), it is preferable to determine a solution’s 
ability to vitrify using differential scanning calorimetry or another method of thermal 
analysis.  Ensuring equilibration throughout the sample lends credence to the successful 
vitrification of macro constructs that cannot easily be tested by calorimetry.  The 
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mathematical model allows determination of the necessary time of exposure for each 
CPA to achieve equilibrium throughout the construct.  Although this can be determined 
experimentally (Mukherjee et al. 2008), the use of a mathematical model is more broadly 
applicable and can be applied to novel tissue-engineered constructs. 
Due to the dependence of cytotoxicity on CPA concentration, exposure time and 
temperature, mass transfer and cytotoxicity are inextricably linked.  The incorporation of 
a cytotoxicity equation based on experimental results for βTC-tet cells allows for insight 
into the importance of each of these variables in the addition and removal protocols.  It is 
important to realize, however, that cytotoxicity parameters dictate the results and will 
vary with cell type.  Cytotoxicity has been shown to increase with increased temperature 
for relatively long exposure times of ~30 minutes (Lawson et al. 2011; Tomford et al. 
1984).  This has led to the general assumption that CPA exposure should be carried out at 
low temperatures (≤ 4°C).  Our results clearly indicate the importance of temperature of 
CPA addition and removal.  The effects of temperature on cytotoxicity are clearly 
exacerbated for the longer exposure times necessary for larger constructs.  Articular 
cartilage is particularly challenging due to the clinically relevant size and dense nature of 
the tissue.  The challenge of mass transfer in articular cartilage is well known and has 
been investigated experimentally.  Pegg’s group has used the “liquidus-tracking method” 
in which CPAs are added as the sample is cooled.  This method attempts to follow the 
liquidus curve of the vitrification solution’s phase diagram to minimize the concentration 
of CPA that the cells are exposed to while ensuring that ice will not form (Pegg et al. 
2006; Wang et al. 2007a).  Although our cytotoxicity parameters were chosen based on 
experimental results with βTC-tet cells, Pegg’s experiments corroborate the need for 
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improved mass transfer.  Our simulations indicate that if the first addition step, A1, is 
carried out at 25°C rather than 4°C, the viable cell number will only drop by 1%.  If A2 is 
also carried out at 25°C, the viable cell number after A1 and A2 will decrease 5%.  As the 
concentration of the addition steps increases, the viable cell number will only decrease.  
While the introduction of the first two steps at room temperature may decrease the time 
necessary for CPA equilibration, the resulting viable cell number will be lower.  
Therefore, the “liquidus-tracking method” or any method that begins CPA exposure at a 
higher temperature and cools during the subsequent addition steps may have limited 
benefit, depending upon the CPA used. 
The issue of overexposure is not often addressed in cryobiology although its 
effects can be significant.  When working with a relatively simple system, such as 
encapsulated cells, overexposure of 1.5 minutes per step can result in additional loss in 
viable cell number (~3%).  While this cell loss may be minimal, these effects are clearly 
exacerbated for larger constructs with more resistance to mass transfer.  In the case of 
articular cartilage, chondrocyte viability is clearly critical to overall performance 
(Hayashi et al. 2009).  Some have suggested the possibility of utilizing lower molecular 
weight CPAs to improve mass transfer and minimize cytotoxicity (Hayashi et al. 2009).  
In order to determine whether a significant increase in diffusivity, either due to a change 
in the matrix or the size of the CPAs, aids the addition and removal process, additional 
simulations were done.  Mass transfer through the articular cartilage slab geometry but 
with mass transfer properties of alginate still requires 30 minutes/step to achieve 
approximately 90% equilibration, as compared to 80 minutes/step for the articular 
cartilage slab (4°C, results not shown).  Although improvement in mass transfer 
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properties would slightly decrease cytotoxicity by approximately 4%, the dimension of a 
clinically relevant cartilage disc plays a larger role in the success or failure of 
vitrification.  It is likely that many researchers, instead of improving diffusivity, are 
achieving only partial equilibration and therefore partial vitrification.  While this may 
minimize CPA toxicity, it will increase the possibility of cryoinjury for cells in the center 
of the disc.  This has been experimentally shown for the vitrification solution VS55, 
composed of DMSO, PD and formamide.  Exposure to VS55 resulted in a decrease in 
chondrocyte viability in articular cartilage discs to 51% although rapid cooling without 
the solution resulted in viability of less than 5% (Guan et al. 2006).  These results 
indicate that the cryoinjury that occurs in the absence of CPAs causes more cell death 
than would be seen due to CPA cytotoxicity experienced by the cells during addition and 
removal.  Cells within the matrix that are exposed to lower concentrations of CPAs that 
are not vitrifiable will likely experience intracellular ice formation, which is almost 
always lethal (Pegg 2010).   
Although experimentally determined, questions may remain about the 
cytotoxicity equation used in these simulations.  The simulated viable cell number after 
addition and removal relies heavily on the parameters chosen.  The cytotoxicity equation 
is most sensitive to a change in parameter f.  When parameter f is halved, f /2, the viable 
cell number is also approximately halved.  Clearly, the need to minimize cytotoxicity can 
be met, in part, with less toxic CPAs.  The theory of cryoprotectant toxicity neutralization 
has been suggested by Fahy (Fahy 2010).  This theory indicates that specific chemicals 
can neutralize the toxicity of CPAs although this has only been shown conclusively for 
the combination of amides with DMSO.  Additionally, many have tried to minimize the 
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concentrations of CPAs necessary to achieve vitrification by using non-permeating 
solutes, such as trehalose or sucrose.  Non-permeating solutes may not contribute as 
significantly to overall toxicity as permeating solutes (Fahy et al. 2004), but previous 
studies have shown that these additives are not innocuous and do contribute to toxicity 
(Lawson et al. 2011).  Less cytotoxic CPAs may be beneficial, but these simulations 
indicate that it may be more critical to use CPAs that exhibit cytotoxicity that is less 
temperature sensitive.  The previous experimental studies indicate that DMSO toxicity is 
less temperature sensitive than that of PD.  Unfortunately, 6M DMSO is not vitrifiable in 
our hands.  The temperature sensitivity of single-component CPAs also carry over to the 
cocktails that are a combination of these CPAs (Lawson et al. 2011).  Nevertheless, the 
issue of CPA cytotoxicity remains the most critical challenge for the successful 
vitrification of tissues or tissue-engineered constructs (Fahy 2010). 
Finally, the use of a time-dependent death rate appears to reflect the 
experimentally determined cytotoxicity kinetics.  The value of parameter f indicates that 
βTC-tet cells become somewhat resistant to CPA cytotoxicity over time.  Depending on 
the mechanism of resistance, it may be possible to select for CPA resistant cells and 
preferentially use these in tissue-engineered constructs.  This phenomenon may be 
present in other cell types to a greater or lesser extent.  It is currently unclear whether the 
use of discrete subpopulations would better represent the physiological phenomenon that 
is occurring although further experiments would be required before the subpopulations 
could be accurately described.  It is clear that investigation into the mechanisms of 
cytotoxicity and resistance would provide insight and allow for better design of CPA 




Vitrification has been touted for use with larger tissue engineered constructs or 
natural tissues where ice formation can be especially detrimental (Kuleshova et al. 2007; 
Pegg 2010).  The issue of CPA cytotoxicity is unavoidable when using the high 
concentrations of CPAs necessary to successfully vitrify a sample.  Simulations indicate 
that temperature of exposure to CPAs is particularly deleterious to viable cell number.  
Cell death can be significantly reduced by using less cytotoxic CPAs.  Additionally, the 
use of CPAs that exhibit less temperature sensitive cytotoxicity would allow the addition 
and removal steps to occur faster at a higher temperature without excessive cell death.  
CPA overexposure also results in significant cell loss, especially when working with 
larger constructs.  On the other hand, CPA underexposure would achieve vitrifiable 
concentrations only at the outer part of a tissue.  These results point to the critical need 
for properly designed protocols that allow for sufficient CPA equilibration while 
minimizing CPA cytotoxicity.  This mathematical model is a useful tool in the design and 




EFFECTS OF CRYOPRESERVATION ON THE CELL AND 
BIOMATERIAL COMPONENTS OF AN ENCAPSULATED CELL 
SYSTEM 
 
The use of microencapsulation to deliver secreting cells has become common in 
the field of Tissue Engineering.  Often overlooked, the preservation of these tissue 
engineered constructs is critical to achieve their widespread clinical use.  In this study, we 
investigated the effects of two types of cryopreservation, conventional freezing and 
vitrification, on the cellular and biomaterial components of calcium alginate/poly-L-
lysine/alginate encapsulated murine insulinomas.  Vitrification was carried out using two 
cocktails, DPS (3M dimethyl sulfoxide + 3M 1,2-propanediol + 0.5M sucrose) and P6 
(1M dimethyl sulfoxide + 5M 1,2-propanediol + 0.34 M poly(ethylene)glycol with M.W. 
of 400).  The cellular and biomaterial components were assessed in vitro and sub-
therapeutically in vivo.  In vitro assessment indicated that metabolically active cell 
number was similar for preserved groups and fresh.  Two different insulin secretion tests 
were performed, which yielded similar results with few minor differences.  Generally, 
beads vitrified with P6 performed comparably to fresh and better than those vitrified with 
DPS.  Sub-therapeutic, week-long, in vivo studies in healthy mice indicated that both 
preserved and fresh beads fared well in vivo with cell growth occurring in all groups after 
implantation.  Biomaterial assessment was done directly after preservation (in vitro 
studies) as well as after explantation.  Preservation did not cause significant damage to 
the beads although conventionally frozen beads occasionally appeared to have ice 
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damage in the calcium alginate matrix.  Upon explantation, biomaterial assessment 
revealed no systematic differences in host response or bead integrity for preserved or 
fresh beads. It is concluded that both conventional freezing and vitrification can be used 
to successfully cryopreserve encapsulated insulinomas. 
5.1 Introduction 
The use of microencapsulation to deliver secreting cells is one of the more 
promising advances in tissue engineering and cell-based therapies.  Long-lasting 
microcapsules, such as those used for pancreatic substitutes, have been shown to increase 
the in vivo immune acceptance of a non-autologous cell implant (de Vos et al. 2006; 
Duvivier-Kali et al. 2001; Schmidt et al. 2008).  Specifically, microencapsulation of islets 
or other insulin-secreting cells has been and continues to be explored for the treatment of 
insulin-dependent diabetes (Cheng et al. 2006; Gross et al. 2007; Safley et al. 2010).  
Preservation is critical in bringing any tissue-engineered construct, including 
encapsulated cell systems, to the clinic (Brockbank et al. 2003; Fahy et al. 2006).  
Cryopreservation provides long-term storage at a temperature where all metabolic, 
chemical and biochemical processes are suspended (Karlsson and Toner 1996).  The two 
main types of cryopreservation being investigated are conventional freezing and 
vitrification.  Conventional freezing utilizes low levels of cryoprotective agents (CPAs), 
slow cooling and rapid warming.  The low concentrations of CPAs are minimally toxic 
but allow ice formation in the extracellular space (Karlsson and Toner 2000).  
Vitrification requires high concentrations of CPAs along with rapid cooling and warming 
to achieve a vitreous, or glassy, state (Brockbank and Taylor 2007).  Step-wise addition 
and removal of CPAs and proper temperature control can help minimize cell death.  
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Despite the additional complexity, vitrification prevents ice damage and is therefore seen 
as a promising method of preservation for tissue-engineered substitutes (Fahy et al. 2004; 
Kuleshova et al. 2007). 
The overarching goal for the cryopreservation of a tissue construct is to maintain 
both the biomaterial and cellular components; however, the importance of each 
component may vary from construct to construct. The performance of an encapsulated 
system utilizing proliferating cells may not be as affected by some loss in cell viability 
because the cells can regenerate.  The biomaterial component, however, cannot 
regenerate.  Previous studies indicate that the ice formed during conventional freezing 
may damage the alginate matrix of an encapsulated system (Heng et al. 2004; Mukherjee 
et al. 2005).  It may also damage the semi-permeable membrane, such as that generated 
by poly-L-lysine treatment, often used to provide immunoprotection.  Damage to either 
of these could compromise the immunoprotective properties and change the overall 
capsule morphology, possibly causing surface roughness which has been shown to affect 
biocompatibility (Bunger et al. 2003).   
This study investigated the cryopreservation of a tissue-engineered pancreatic 
substitute consisting of βTC-tet murine insulinomas encapsulated in calcium-
alginate/poly-L-lysine/alginate (APA) beads.  Encapsulated cells were subjected to 
conventional freezing in 10% dimethyl sulfoxide (DMSO) or vitrification using one of 
two vitrification solutions.  The cellular and biomaterial components of this system were 
evaluated after warming and compared to the unpreserved control.  For the cellular 
component, the metabolically active cell number and insulin secretion rates were 
determined.  The biomaterial component was assessed for overall integrity via histology 
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and mechanical testing and for poly-L-lysine (PLL) layer integrity by permeability 
studies using fluorescently-labeled dextran.   
5.2 Materials and Methods 
5.2.1 Cell Culture 
βTC-tet cells were obtained from the laboratory of Dr. Efrat, Albert Einstein 
College of Medicine, Bronx, NY (Fleischer et al. 1998).  Monolayer cultures were 
initiated from frozen stocks and propagated in T-flasks in complete growth medium 
consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, St. Louis, 
MO) supplemented with 10% fetal bovine serum (Gemini Bioproducts, West 
Sacramento, CA), 1% L-glutamine (Mediatech, Inc., Manassas, VA) and 1% 
penicillin/streptomycin (Mediatech, Inc.).  Cells were cultured in a humidified incubator 
at 37°C and 5% CO2.  Cells were split at a ratio of 1:5 and experiments performed with 
passages 38-44. 
5.2.2 Encapsulation and Coating 
βTC-tet cells were encapsulated using previously published protocols (Stabler et 
al. 2001).  Briefly, cells were detached from monolayer cultures by trypsinization (0.25% 
Trypsin-EDTA, Mediatech Cellgro) and suspended at a density of 3.0x107cells/ml in 2% 
sodium alginate (Pronova Ultra Pure LVM alginate NovaMatrix of FMC BioPolymer AS, 
Norway).  Beads were formed using an electrostatic bead generator (Nisco Engineering 
AG, Zurich, Switzerland) that generated droplets which fell into a well-stirred 1.1% 
CaCl2 bath.  Cross-linked beads were washed and stored in complete growth medium and 
cultured overnight in a non-treated T-flask on a rocker plate in a 37°C and 5% CO2, 
humidified incubator.  Beads were coated with poly-L-lysine as previously described 
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(Stabler et al. 2001).  In short, beads were subjected to subsequent treatments with CaCl2, 
CHES, PLL (Sigma, MW: 19,200), and 0.2% alginate (same type as above).  They were 
washed and stored in complete growth medium and cultured overnight as indicated 
above.   
5.2.3 Vitrification and Conventional Freezing Protocols 
Two different vitrification solutions were used, DPS (3M DMSO +3M 1,2-
propanediol (PD)+0.5M sucrose) and P6 (1M DMSO+5M PD +0.34M polyethylene 
glycol with a molecular weight of 400).  Both were prepared using a concentrated and 
modified version of the EuroCollins carrier solution containing 174.76 g/L dextrose, 5.6 
g/L KCl, 4.2 g/L NaHCO3 and 8.2 g/L NaCl.  This concentrated EuroCollins solution was 
diluted in the final solution volume at a ratio of 1:5.  All chemicals were from Sigma-
Aldrich except sucrose and NaHCO3 (Fisher, Fair Lawn, NJ).  CPA solutions were added 
to encapsulated cells in a step-wise manner at 4°C as shown in Table 5.1.  Rapid cooling 
from 4°C to -100°C at ~100°C/min was achieved by immersion in an isopentane bath 
held at -135°C; this was followed by slower cooling from -100°C to -135°C at ~2°C/min 
in the vapor phase of a mechanical freezer (Sanyo, San Diego, CA) set at -135°C.  
Samples were stored overnight before warming rapidly in a bath of 30% DMSO in water 
at room temperature.  CPAs were removed in a step-wise manner at room temperature 
(Table 5.1).  Conventionally frozen (CF) beads were exposed to 10% DMSO in complete 
growth medium for 10 minutes at 4°C and then transferred to cryovials (Corning Inc., 
Corning, NY).  These were placed in an isopropyl alcohol bath (Nalgene of Thermo 
Fisher Scientific, Rochester, NY) in a -80°C mechanical freezer (VWR, West Chester, 
PA) for 90 minutes before being plunged into liquid nitrogen.  Vials were stored 
84 
 
overnight before being rapidly warmed by agitation in a 37°C water bath until all visible 
ice had melted.  Beads were then incubated in complete growth medium for 10 minutes at 




DPS P6 Temp 
(°C) 
Step [DMSO] [PD] [Sucrose]
Time 
(min) [DMSO] [PD] [PEG] 
Time 
(min) 
A1  1  1  0.15  2  0.25  1  0  3  4  
A2  2  2  0.3  2  0.5  2  0.1  3  4  
A3  3  3  0.5  2  0.75  3.5  0.2  3  4  
A4  --  --  --  --  1  5  0.338  3  4  
R1  2.25  2.25  0.3  2  0.75  4  0.2  2  RT  
R2  1.5  1.5  0.2  2  0.5  2  0.2  2  RT  
R3  0.75  0.75  0.1  2  0.25  1  0  2  RT  




5.2.4 Metabolically Active Cell Number and Secretory Function 
Metabolically active cells and rates of insulin secretion were measured 
immediately post-warming.  To determine the metabolic activity of cells, 100 µL of APA 
beads with 100 µL alamarBlue™ (Invitrogen™, Carlsbad, CA) and 1 mL complete 
growth medium, or only 100 µL alamarBlue™ and 1.1 mL complete growth medium for 
controls, were placed in each well of a 12 well plate for 3 hours in a 37°C and 5% CO2, 
humidified incubator.  A 100 µL supernatant volume from each well was transferred to a 
Table 5.1. Addition & removal protocols for DPS and P6. RT indicates room temperature. 
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black 96 well plate and read using a SPECTRAMAX Gemini Fluorescent plate reader 
(Molecular Devices, Sunnyvale, CA) using an excitation and an emission wavelength of 
544 and 590 nm, respectively.  Data were normalized to those from untreated beads.   
Live-Dead imaging of cells in beads was performed using the LIVE/DEAD® Viability 
Cytotoxicity Kit (Molecular Probes® by Invitrogen™, Carlsbad, CA).  Beads were 
incubated for 20 minutes in 0.9% NaCl containing 2µM calcein AM and 4µM ethidium 
homodimer-1, and images were acquired using an LSM 510 UV confocal microscope 
(Carl Zeiss, Inc, Thornwood, NY) with excitation at wavelengths of 488 nm and 543 nm.   
To determine high-glucose insulin secretion, 100 µL of APA beads were 
incubated with complete growth medium for one hour in a 37°C and 5% CO2, humidified 
incubator.  Samples were taken at t=0 and at t=1 hr and stored at -80°C for later assay of 
insulin with a Mouse Insulin ELISA (Mercodia, Uppsala, Sweden).  To measure basal 
and stimulated insulin secretion, 100 µl of APA beads were subjected to a one hour basal 
period followed by a 30 minute stimulated period.  Basal medium consisted of glucose- 
and glutamine-free DMEM (Sigma-Aldrich) supplemented with 1.31 g/L bovine serum 
albumin (Sigma), and stimulation medium consisted of DMEM (Sigma) with 15 mM 
glucose and supplemented with FBS, L-glutamine and penicillin/streptomycin at the 
same concentrations as in complete growth medium.  Encapsulated cells were incubated 
in a 37°C humidified incubator with 5% CO2 during both secretion periods.  Samples 
were taken directly before and after the basal and stimulated periods, stored at -80°C and 





5.2.5 Biomaterial Integrity 
Permeability was assessed by incubating APA beads with fluorescently-labeled 
dextran (FITC-dextran) of 20 and 70 kDa molecular weights (Sigma).  FITC-dextran was 
introduced at a final concentration of 0.025 mg/ml in 0.9% NaCl and images were taken 
at 1, 2, 3, 4, 5, 10, 15, 30 and 60 minutes using the LSM 510 UV confocal microscope.  
Young’s moduli of preserved and fresh beads were determined using uniaxial 
compression.  An EnduraTec ElectroForce® 3100 (Bose, Eden Prairie, MN) was used to 
deliver a compression rate of 0.01 mm/s with a 0.5N load cell (Interface Inc., Scottsdale, 
AZ).  Compression was carried out to a final deformation of 10% or less.  Hertz’s theory 
was used to calculate the Young’s moduli (Liu et al. 1998).  For histology, APA beads 
were fixed in 2% glutaraldehyde (Sigma) in 0.9% NaCl and subsequently embedded 
using the Immunobed Embedding Kit (Electron Microscopy Sciences, Hatfield, PA).  To 
minimize changes in bead morphology caused by the embedding process, embedding was 
performed with increasing concentrations of resin in double-distilled water, similar to 
previously reported procedures (James et al. 2004).  After embedding, 5 µm sections 
were sliced with a Microm 355H Microtome (Thermo Fisher Scientific, Walldorf, 
Germany), mounted and stained with 1% Toluidine Blue (Research Organics, Cleveland, 
OH) to visualize the alginate matrix.   
5.2.6 Statistical Analysis 
Statistical calculations were performed using a one-way ANOVA and Tukey’s 
test to determine differences between test groups.  Values of p<0.05 were considered to 





5.3.1 Metabolically Active Cell Number and Secretory Function 
Metabolically active cell numbers for DPS, P6 and conventionally frozen (CF) 
samples were normalized to previous day fresh and were 0.71 ± 0.13, 0.79 ± 0.10, and 
0.88 ± 0.20, respectively.  No statistical differences were found among any of the fresh or 
cryopreserved groups (n=5).  Results for insulin secretion measured post-warming are 
shown in Figure 5.1.  APA beads preserved by conventional freezing had lower insulin 
secretion than fresh beads or beads vitrified with P6 when subjected to incubation in 
high-glucose medium; there were no significant differences between either of the vitrified 
groups and the fresh with n=9 (Fig. 5.1a).  A somewhat different trend was observed in 
the stimulated insulin secretion tests, n=4 (Fig. 5.2b).  In these, during the basal period, 
beads vitrified using P6 secreted more insulin than all other groups, including the fresh 
control.  However, no significant differences were found among the stimulated secretion 
levels or among the stimulation indices (stimulated rate over basal secretion rate) of the 
groups.  The stimulation indices were 1.97 ± 0.58, 2.39 ± 0.54, 1.72 ± 0.28, and 2.54 ± 













   Basal 
   Stimulated 
A) 
B) 
Figure 5.1. Insulin secretion for A) high-glucose exposure over 1 hr period, n=9 and B) 
basal (0 mM glucose, 1 hr) and stimulated (15 mM glucose, 30 min), n=4.  
#,*, ‡ indicate p<0.05 between groups.  
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5.3.2 Biomaterial Integrity  
Assessment of permeability through the PLL layer after vitrification and 
conventional freezing indicated that no functional damage was done to the layer during 
preservation (n=3).  Indeed, with all groups, FITC-labeled dextran with M.W. of 20 kDa 
permeated almost completely within 15 minutes while FITC-dextran with M.W. of 70 
kDa permeated only slightly over one hour.  Results for FITC-dextran with M.W. of 70 
kDa are shown in Figure 5.2.  A total of 4 independent samples from each preparation 
were processed post-warming for histology, and representative images are shown in 
Figure 5.3.  Images in Figure 5.3(A) show representative beads from fresh and the three 
cryopreservation treatments.  An additional conventionally frozen sample is shown in 
Figure 5.3(B) as it indicates possible ice damage to the calcium alginate matrix.  This 
image was included because similar images were seen in previous studies (Mukherjee et 
al. 2005), although in the present study this morphology appeared only once in the n=4.  
Figure 5.4 shows the average diameters and Young’s Moduli of the fresh and 














Figure 5.3. Typical histology images from a total of n=4 of fresh and cryopreserved 
beads  (A).  A conventionally frozen bead exhibiting what appears to be ice damage is 
shown in (B).  
Figure 5.2. Fresh or cryopreserved beads after 1 min or 30 min incubation in FITC-
labeled dextran (70 kDa) solution and at 1 hr after dextran solution was removed.  








Vitrification has been touted to be the most promising method of preservation for 
tissue engineered constructs due to the elimination of ice (Kuleshova et al. 2007).  In our 
studies, we investigated the post-warming cellular viability and secretory function, as 
well as the biomaterial integrity, of encapsulated insulin-secreting cells that may serve as 
a pancreatic tissue substitute.  As stated previously, the metabolically active cell number 
was not statistically different among any of the fresh and preserved groups.  The insulin 
secretion results for the two different tests were not entirely consistent; however, a few 
general trends arose.  Between the vitrified groups, P6 appeared to outperform DPS.  
Also, beads vitrified with P6 were generally comparable to fresh.   
Figure 5.4. Young’s moduli (solids) and bead diameters (stripes) for fresh and 
cryopreserved beads, n=3. No statistically significant differences found. 
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Although the reasons for the insulin secretion inconsistencies are unclear, one 
notable difference is the increased basal insulin secretion of beads vitrified with P6 
(Figure 5.1B).  Recent studies have shown that cryopreservation increases oxidative 
stress (Tatone et al. 2010) and specifically the intracellular concentration of hydrogen 
peroxide (Kim et al. 2010) in reproductive cells.  Increased intracellular hydrogen 
peroxide has been shown to cause a transient increase in insulin secretion from islets 
(Maechler et al. 1999).  It is possible that the P6 vitrification solution may cause more 
oxidative stress than DPS, as it has been shown to be more cytotoxic (Lawson, Ahmad et 
al. 2011).  This may have then resulted in a transient increase in insulin secretion 
observed under basal conditions with P6 and may have caused insulin secretion 
comparable to fresh when beads were subjected to high-glucose medium (Figure 5.1A).  
Although the results from the two insulin secretion tests indicate small differences in 
secretion among groups, these differences were not reflected in vivo, probably due to 
cellular proliferation over the 7-day period of these studies.         
Cell viability and function are critical for the in vivo success of an implant, but the 
biomaterial integrity also affects the performance of the construct.  Previous studies 
indicated that ice damage occurs within the calcium alginate matrix of a conventionally 
frozen tissue-engineered pancreatic substitute (Mukherjee et al. 2005); however similar 
damage was seen only occasionally throughout our studies.  Due to the low CPA 
concentrations used in conventional freezing, extracellular ice formation is expected to 
occur, although it is possible that ice crystals form in the solution in-between the cross-
linked alginate chains, thus not damaging the matrix. Furthermore, any ice formation that 
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may have occurred in conventional freezing did not appear to affect the integrity of the 
poly-L-lysine layer or the stiffness of the beads.   
5.5 Conclusions 
Although literature touts the use of vitrification to preserve tissue-engineered 
constructs, it appears that APA-encapsulated cells may be successfully preserved using 
either vitrification or conventional freezing.  In vitro studies indicated some differences 
in the performance of the conventionally frozen and vitrified beads as assessed by insulin 
secretion and metabolic activity.  However, there were no significant differences in the 
biomaterial component.  It remains unclear whether ice formation may affect the in vivo 




THE EFFECTS OF CRYOPRESERVATION ON THE IN VIVO EFFICACY OF 
AN ENCAPSULATED CELL SYSTEM 
 
Cryopreservation is a critical step in bringing any tissue-engineered system from 
the benchtop to the clinic.  There are two main types of cryopreservation: conventional 
freezing and vitrification.  Conventional freezing uses low concentrations of 
cryoprotective agents (CPAs) and allows ice formation while vitrification utilizes high 
concentrations of CPAs to eliminate ice formation.  In this study, we investigated the 
effects of these methods of cryopreservation on the in vivo performance of calcium 
alginate/poly-L-lysine/alginate encapsulated murine insulinomas.  Vitrification was 
carried out using two cocktails, DPS (3M dimethyl sulfoxide + 3M 1,2-propanediol + 
0.5M sucrose) and P6 (1M dimethyl sulfoxide + 5M 1,2-propanediol + 0.34M 
poly(ethylene)glycol with M.W. of 400).  Conventional freezing was done using 10% 
dimethyl sulfoxide in complete growth medium.  Sub-therapeutic studies were done with 
healthy mice receiving a small volume of fresh or preserved beads.  Beads were 
explanted on days 2 and 7.  Biomaterial assessment indicates possible ice damage in 
some conventionally frozen explants.  Insulin secretion results indicate that beads 
vitrified with DPS perform worse within the first two days but that all cells exhibit 
growth during the sub-therapeutic in vivo period.  For therapeutic studies, diabetic mice 
were implanted with fresh or preserved beads.  Mice were sacrificed upon construct 
failure or at 2 weeks and beads were explanted for analysis.  In vivo performance of 
conventionally frozen beads was comparable to fresh beads with both groups achieving 
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normoglycemia (50-250 mg/dl) relatively quickly and maintaining normoglycemia for 
the majority of the experiment.  Vitrified groups performed worse with beads vitrified 
with DPS or P6 reverting only 3 of 8 mice or 5 of 8 mice, respectively.  Beads vitrified 
with DPS also took significantly longer to revert than fresh or conventionally frozen.  
Biomaterial assessment of the explants indicated that all groups experienced similar host-
cell attachment and damage in vivo.  The ice formation that occurs during conventional 
freezing did not significantly damage the encapsulated cell system or its in vivo 
performance.  Insulin secretion results for the explanted beads indicated that all preserved 
groups secreted significantly less insulin than fresh.  Although ice has been shown to be 
detrimental to some biomaterials, our in vivo results indicate that conventional freezing is 
the better method for preservation of an encapsulated cell system.       
6.1 Introduction 
Although often overlooked, cryopreservation is considered by many to be critical 
in bringing tissue engineered constructs from the benchtop to the clinic with off-the-shelf 
availability (Pancrazio et al. 2007; Sambanis 2000).  Two main methods of 
cryopreservation are currently being investigated for the preservation of constructs: 
conventional freezing and vitrification.  In conventional freezing, a low level of 
cryoprotective agent (CPA) is added and the sample is slowly cooled, stored and thawed 
by rapid warming.  Vitrification is more complex and requires multi-step addition of high 
concentrations of CPAs and rapid cooling and warming.  Both methods have 
disadvantages.  The conventional freezing method allows ice formation (Brockbank and 
Taylor 2007; Karlsson and Toner 1996) while the solutions used in vitrification are more 
cytotoxic due to the higher concentrations of CPAs (Saragusty et al. 2009).  However, 
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aside from these disadvantages it is difficult to confidently determine which preservation 
method may be preferable for a specific tissue-engineered construct due to the high 
variability of results reported in literature.   
An example of this is the preservation of encapsulated cell systems which are 
widely used in the field of Tissue Engineering to deliver cells and are broadly applicable.  
The preservation of microencapsulated insulin-secreting cells in particular has been 
widely investigated although the results have been highly variable.  Conventional 
freezing has been shown to be successful in maintaining encapsulated islets (Schneider 
and Klein 2011; Stiegler et al. 2006) and myoblasts (Murua et al. 2009) as well as their 
function when implanted.  Alginate encapsulation has been shown to benefit conventional 
freezing, as encapsulated cells fare better during conventional freezing than free cells or 
cell clusters do (Malpique et al. 2010).  However, other groups have reported that 
conventional freezing leads to damage in the alginate or agarose matrix of an 
encapsulated system (Agudelo and Iwata 2008; Hang et al. 2010; Heng et al. 2004; 
Mukherjee et al. 2005).  The ice formation that occurs in conventional freezing is clearly 
detrimental for constructs that serve a biomechanical function, such as heart valves 
(Schenke-Layland et al. 2007).  Ice formation may also detrimentally affect the 
performance of an encapsulated system by changing the mechanical strength or overall 
morphology of the encapsulation material.  Surface roughness has been shown to affect 
the in vivo inflammatory response (Bunger et al. 2003; Lanza et al. 1991).  The ice-free 
method of preservation, vitrification, has been used to successfully cryopreserve 
encapsulated cells and islets, although none of these studies have compared the 
performance of conventional freezing to vitrification within the context of in vivo 
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efficacy (Agudelo et al. 2009; Wu et al. 2007).  Additionally, alginate encapsulation 
appears to aid in the thermal transition of the sample to the vitreous state by causing 
preferential vitrification of water in the alginate bead compared to the bulk water (Zhang 
et al. 2010).   
This study was designed to directly compare the two cryopreservation methods, 
vitrification and conventional freezing, and determine their effects on the in vivo 
performance of an encapsulated cell system.  Insulin-secreting βTC-tet murine 
insulinomas were encapsulated in calcium-alginate/poly-L-lysine/alginate (APA) beads 
and were subjected to conventional freezing in 10% dimethyl sulfoxide (DMSO) or 
vitrification using one of two vitrification solutions.  In sub-therapeutic studies, fresh or 
cryopreserved beads were implanted in healthy mice and were explanted on days 2 and 7 
for assessment of the biomaterial and cell function. For therapeutic studies, 
streptozotocin-induced diabetic mice were implanted with fresh or cryopreserved beads 
and the in vivo performance and ex vivo cell function and biomaterial component of the 
implants were assessed. 
6.2 Materials & Methods 
6.2.1 Cell Culture 
βTC-tet cells were obtained from the laboratory of Dr. Efrat at the Albert Einstein 
College of Medicine, Bronx, NY (Fleischer et al. 1998).  Monolayer cultures were 
initiated from frozen stocks and propagated in T-flasks in complete growth medium 
consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, St. Louis, 
MO) supplemented with 10% fetal bovine serum (Gemini Bioproducts, West 
Sacramento, CA), 1% L-glutamine (Mediatech, Inc., Manassas, VA) and 1% 
98 
 
penicillin/streptomycin (Mediatech, Inc.).  Cells were incubated in a humidified incubator 
at 37°C and 5% CO2.  Cells were split at a ratio of 1:5 and experiments performed with 
passages 38-44. 
6.2.2 Encapsulation and Coating 
βTC-tet cells were encapsulated using previously published protocols (Stabler et 
al. 2001).  Briefly, cells were detached from monolayer cultures by trypsinization (0.25% 
Trypsin-EDTA, Mediatech Cellgro) and suspended at a density of 6.0x106 cells/ml (sub-
therapeutic) or 1.0x107cells/ml (therapeutic) in 2% sodium alginate (Pronova Ultra Pure 
LVM alginate NovaMatrix of FMC BioPolymer AS, Norway).  Beads were formed using 
an electrostatic bead generator (Nisco Engineering AG, Zurich, Switzerland) that 
generated droplets which fell into a well-stirred 1.1% CaCl2 bath.  Cross-linked beads 
were washed and stored in complete growth medium and cultured overnight (sub-
therapeutic) or for 4-6 hours (therapeutic) in a non-treated T-flask on a rocker plate in a 
37°C and 5% CO2, humidified incubator.  Beads were coated with poly-L-lysine (PLL) as 
previously described (Stabler et al. 2001).  In short, beads were subjected to subsequent 
treatments with CaCl2, 2-(Cyclohexylamino) ethanesulfonic acid, PLL (Sigma, MW: 
19,200), and 0.2% alginate (same type as above).  They were washed and stored in 
complete growth medium and cultured overnight as indicated above.   
6.2.3 Vitrification and Conventional Freezing Protocols 
Two different vitrification solutions were used, DPS (3M DMSO +3M 1,2-
propanediol (PD)+0.5M sucrose) and P6 (1M DMSO+5M PD +0.34M polyethylene 
glycol with a molecular weight of 400).  Both were prepared using a concentrated and 
modified version of the EuroCollins carrier solution containing 174.76 g/L dextrose, 5.6 
99 
 
g/L KCl, 4.2 g/L NaHCO3 and 8.2 g/L NaCl.  This concentrated EuroCollins solution was 
diluted in the final solution volume at a ratio of 1:5.  All chemicals were from Sigma-
Aldrich except sucrose and NaHCO3 (Fisher, Fair Lawn, NJ).  Solutions were added to 
encapsulated cells in a step-wise manner at 4°C as shown in Table 5.1.  Rapid cooling 
from 4°C to -100°C at 100°C/min was achieved by immersion in an isopentane bath held 
at -135°C; this was followed by slower cooling from -100°C to -135°C at 2°C/min in the 
vapor phase of a mechanical freezer (Sanyo, San Diego, CA) set at -135°C.  A dummy 
vial with a thermocouple in the final vitrification solution was used to measure cooling 
rates.  Samples were stored overnight before warming rapidly in a bath of 30% DMSO in 
water at room temperature.  CPAs were removed in a step-wise manner at room 
temperature (Table 5.1).  Conventionally frozen (CF) beads were exposed to 10% DMSO 
in complete growth medium for 10 minutes at 4°C and then transferred to cryovials 
(Corning Inc., Corning, NY).  These were placed in an isopropyl alcohol bath (Nalgene 
of Thermo Fisher Scientific, Rochester, NY) in a -80°C mechanical freezer (VWR, West 
Chester, PA) for 90 minutes before being plunged into liquid nitrogen (-196°C).  Vials 
were stored overnight before being warmed by agitation in a 37°C water bath until all 
visible ice had melted.  Beads were then incubated in complete growth medium for 10 
minutes at 37°C and washed with complete growth medium.   
6.2.4 Sub-therapeutic in vivo Techniques 
All in vivo procedures were done in compliance with the Georgia Tech 
Institutional Animal Care and Use Committee.  Sub-therapeutic studies were carried out 
in 5-week old, healthy Balb/c mice (The Jackson Laboratory, Bar Harbor, ME).  Prior to 
implantation, preserved or fresh beads were washed three times with unsupplemented 25 
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mM glucose DMEM (Sigma-Aldrich).  Briefly, mice were anesthetized to a surgical 
plane with 1.5% isoflurane in oxygen.  Hair was removed from the surgical site, which 
was prepped with chlorhexadine and isopropyl alcohol.  A small midline abdominal 
incision was made through the skin and a 16 gauge needle was inserted to deliver 0.2 ml 
fresh or preserved beads.  The muscle layer was closed with sutures and the skin layer 
with wound clips.  Mice were allowed to recover until ambulatory before subcutaneous 
administration of 0.05 mg/kg buprenorphine.  Blood glucose levels were monitored daily 
throughout the experiment using the Truetrack Blood Glucose Monitoring System 
(CVS/pharmacy, Woonsocket, RI).  Mice with blood glucose less than 100 mg/dL were 
given 1 mg/ml tetracycline (Sigma-Aldrich) in 2.5% sucrose (Fisher) solution as a 
replacement for water to regulate growth of the encapsulated βTC-tet cells (Black et al. 
2006; Simpson et al. 2005).  Mice were euthanized by asphyxiation on Days 2 and 7 post-
implantation. 
6.2.5 Therapeutic in vivo Techniques   
For therapeutic studies, 10-week old male Balb/c mice (The Jackson Laboratory) 
were injected with repeated doses of streptozotocin (Sigma) in 0.09M citrate buffer 
solution (Sigma) at a dosage of 210 mg/kg.  Mice were considered diabetic after two 
consecutive non-fasting blood glucose levels of 350 mg/dL or higher.  Blood glucose 
levels were monitored using the Truetrack Blood Glucose Monitoring System 
(CVS/pharmacy).  After confirmation of a diabetic state, mice were implanted with 0.3 
ml of fresh or preserved alginate/poly-L-lysine/alginate (APA) beads.  Surgery 
procedures were the same as for sub-therapeutic studies.  Immediately post-implantation, 
the implant was considered to have failed if blood glucose levels did not fall within the 
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defined normoglycemic range (50-250 mg/dL) within four days.  Thereafter, constructs 
were considered to have failed when two consecutive blood glucose readings were above 
250 mg/dL.  Mice with blood glucose less than 100 mg/dL were given 4 mg/ml 
tetracycline (Sigma-Aldrich) in 2.5% sucrose (Fisher) solution as described above.  Mice 
were sacrificed and explants retrieved upon construct failure or 14 days after 
implantation.  Mice were euthanized by CO2 asphyxiation. 
6.2.6 Post-Explantation Assessment 
To determine high-glucose insulin secretion, 100 µL of APA beads were 
incubated with complete growth medium for one hour in a 37°C and 5% CO2, humidified 
incubator.  Samples were taken at t=0 and at t=1 hour and were analyzed with a Mouse 
Insulin ELISA (Mercodia, Uppsala, Sweden).   
Live-Dead imaging of cells in beads was performed using the LIVE/DEAD® 
Viability Cytotoxicity Kit (Molecular Probes® by Invitrogen™, Carlsbad, CA).  Beads 
were incubated for 20 minutes in 0.9% NaCl containing 2µM calcein AM and 4µM 
ethidium homodimer-1, and images were acquired using an LSM 510 UV confocal 
microscope (Carl Zeiss) with excitation at 488 nm and 543 nm.  Histological images were 
obtained as follows.  APA beads were fixed in 2% glutaraldehyde (Sigma) in 0.9% NaCl 
and subsequently embedded using the Immunobed Embedding Kit (Electron Microscopy 
Sciences, Hatfield, PA).  To minimize changes in morphology caused by the embedding 
process, embedding was performed with increasing concentrations of resin in double-
distilled water similarly to previously reported procedures (James et al. 2004).  After 
embedding, 5 µm sections were sliced with a Microm 355H Microtome (Thermo Fisher 
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Scientific, Walldorf, Germany), mounted and stained with 1% Toluidine Blue (Research 
Organics, Cleveland, OH) to visualize the alginate matrix.   
6.2.7 Statistical Analysis 
Statistical calculations were performed using a one-way ANOVA and Tukey’s 
test to determine differences between test groups.  Values of p<0.05 were considered to 
indicate statistically significant differences.     
6.3 Results 
6.3.1 Sub-therapeutic in vivo Studies 
Results for high-glucose insulin secretion from beads before implantation and 
from beads explanted from mice on Days 2 and 7 are shown in Figure 6.1.  Although 
there were no differences between groups pre-implantation, beads vitrified with DPS 
performed significantly worse than fresh and the other preserved groups after two days in 
vivo.  By day 7, the performance of the beads became highly variable and any differences 
were masked.  Several mice from each group received tetracycline to arrest cell growth 
due to lower blood glucose levels.  In spite of this, insulin secretion appeared to increase 













Figure 6.1. Sub-therapeutic high-glucose insulin secretion for fresh and preserved 
groups pre-implantation and at 2 and 7 days post-explantation, n=3. * indicates 















Figure 6.3. Sub-therapeutic Live-Dead imaging for explanted beads, day 7.  Images 
representative of n=3.   
Figure 6.2. Sub-therapeutic histology for explanted beads, day 7.  Images 
representative of n=3. 
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Histological images of beads explanted on day 7 are shown in Figure 6.2.  The 
levels of host-cell attachment were highly variable and there were no noticeable trends 
across groups.  The alginate matrix appeared to be damaged in some conventionally 
frozen explants.  Live-Dead imaging (Figure 6.3) revealed no correlation between host-
cell attachment and cell viability within the constructs.  In most of the explanted beads, 
the majority of the cells were alive, and images indicated significant cell growth by day 
7.  However, upon explantation, beads vitrified using DPS exhibited greater variability 
than the other groups, with several explants yielding DPS beads with high viability as 
well as beads with only dead cells.  Generally, these images revealed single dead cells or 
larger clusters of mostly living cells.  
6.3.2 Therapeutic in vivo Studies 
Overall in vivo performance of preserved and fresh beads is shown in Figure 
6.4A.  Average blood glucose levels for mice are given in Figure 6.4B.  Fresh and 
conventionally frozen beads performed comparably, with both groups lowering blood 
glucose levels to less than 250 mg/dl relatively quickly and maintaining blood glucose 
within the defined range (50-250 mg/dl) for the majority of the experiment.  Mice 
implanted with either of the vitrified groups did not perform as well as those given fresh 
beads.  Of the two vitrified groups, beads vitrified with DPS did not appear to perform as 
well as those vitrified with P6.  Mice implanted with DPS-vitrified beads took 
significantly longer to revert to the defined normoglycemic range than fresh or 
conventionally frozen.  Table 6.1 shows the number of implants from each group that was 
able to revert mice to the normoglycemic range for more than two days.  Three implants 
vitrified with DPS were unable to revert mice to normoglycemia within four days and 2 
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additional implants were only able to revert mice for one or two days.  Of the 8 mice 
implanted with DPS-vitrified beads, only 3 mice achieved and maintained blood glucose 
levels within the defined normoglycemic range.  Beads vitrified with P6 were slightly 
more efficacious with only 3 of 8 implants failing and the rest maintaining 























Figure 6.4. A) Days post-implantation to revert mice to normoglycemia and total days of 
normoglycemia B) Average blood glucose levels.  n=3-9: n-value decreased as mice were 
sacrificed. * indicates p<0.05.  





Number of constructs maintaining normoglycemia 
in mice for more than two days 
Fresh  7  out of 8 
Conventionally Frozen  8 out of 8 
Vitrified (DPS)  3 out of 8 




Mice were explanted upon failure or after 14 days.  Post-explantation insulin 
secretion is shown in Figure 6.5.  These results include explants that failed although 
trends were similar when the failed explants were excluded (data not shown).  All 
preserved groups secreted significantly less insulin than fresh.  Biomaterial assessment of 
explanted beads is shown in Figures 6.6-6.8.  Pre-implantation microscopy of fresh and 
preserved groups is also shown in Figure 6.6 for comparison.  Explanted beads exhibited 
variability between mice and between beads from a single explant.  Microscopy images 
reveal cell growth, host-cell attachment and occasional damage to the beads.  This 
damage appears to have occurred during the in vivo period and occurred to some extent in 
all groups.  Live-Dead Imaging (Figure 6.7) reveals similar trends but also shows single 
dead cells in premature explants and living cell clusters in successful implants.  
Histological images (Figure 6.8) show cell growth and in vivo damage to the beads.     
Table 6.1. In vivo efficacy of implants in 








Figure 6.6. Microscopy of fresh and cryopreserved beads A) before implantation, B) 
explanted after 14 days in vivo and C) prematurely explanted due to “failure”, scale bar 
indicates 500 µm. D5 and D11 indicate days of explants, day 5 and day 11, respectively.  
Figure 6.5. Post-explantation insulin secretion including “failed” explants. #,*,‡ indicates 
p<0.05 when comparing groups. n=8 for CF, DPS, P6, n=5 for fresh.  
A) Pre-implantation            B) Explanted Day 14 








Figure 6.8. Histological images of beads A) explanted after 14 days in vivo and B) 
prematurely explanted due to “failure”.  
Figure 6.7. Live-Dead imaging of beads A) explanted after 14 days in vivo and B) 
prematurely explanted due to “failure”. D6 and D4 indicate days of explants, day 6 and 
day 4, respectively. 
A) Explanted Day 14             B) Premature Explants 




6.4.1 Sub-therapeutic in vivo Studies 
To determine the best method of preservation for a tissue-engineered construct, it 
is critical to compare the in vivo performance of both vitrified and conventionally frozen 
constructs as well as the fresh or unpreserved control.  Although significant research has 
been done to determine the efficacy of vitrification, little of this work has compared 
vitrified to conventionally frozen or investigated the in vivo performance.  Sub-
therapeutic studies were done to allow for direct comparison of biomaterial and cellular 
function at two time points: days 2 and 7.  These studies revealed that beads vitrified 
using DPS secreted significantly less insulin than all other groups after explantation on 
day 2.  However, all groups fared well in vivo and insulin secretion studies paired with 
Live-Dead imaging indicate that the cellular component does regenerate in vivo.  
Biomaterial assessment indicated that both fresh and preserved beads experienced 
minimal host response within the seven days of the experiment.  These results suggest 
that preserved groups may perform comparably to fresh although it was unclear whether 
beads vitrified with DPS would recover quickly enough to have a therapeutic effect in 
vivo.  The in vivo therapeutic efficacy of a tissue-engineered construct remains the 
ultimate assessment of success.   
6.4.2 Therapeutic in vivo Studies 
In therapeutic studies, conventionally frozen beads were found to perform 
comparably to fresh, both in the time necessary to revert diabetes and in the number of 
mice maintained in the normoglycemic range throughout the experiment.  The success of 
conventional freezing in the preservation of alginate-encapsulated cells is not 
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unprecedented (Malpique et al. 2010; Stiegler et al. 2006) and is likely due to the nature 
of the encapsulation.  Cells were suspended in alginate without adhesive motifs resulting 
in an environment similar to a cell suspension.  Ice forms preferentially in the 
extracellular matrix of the alginate (Karlsson and Toner 2000) which may not 
detrimentally affect the cells suspended in the alginate.   
Vitrified beads did not perform as well as conventionally frozen or fresh beads.  
Beads vitrified using P6 or DPS reverted diabetes in only 5 of 8 or 3 of 8 mice, 
respectively.  Additionally, beads vitrified with DPS took significantly longer to revert 
diabetes than either fresh or conventionally frozen (Figure 6.4).  These results corroborate 
the sub-therapeutic performance of beads vitrified with DPS and indicate that the cellular 
component may not have had sufficient time to regenerate and have a therapeutic effect.  
Previous studies from our laboratory indicate comparable or better in vitro performance 
of vitrified alginate beads when compared to conventionally frozen beads (Mukherjee et 
al. 2005).  It is not entirely clear why vitrification resulted in such poor in vivo 
performance in these studies.  The high concentrations of CPAs present in the 
vitrification solutions are cytotoxic and cause a loss of cell viability (Lawson 2011).  
These effects may be amplified in the current studies due to the low cell density.  A low 
dose was necessary in sub-therapeutic studies to minimize the therapeutic effect.  
Additionally, therapeutic studies required a low cell density due to the implant volume, 
therapeutic dose of cells and need to retrieve beads after euthanization.  Post-explantation 
assessment required a minimum measurable volume of 0.05 ml beads.  An implant 
volume of 0.3 ml was chosen to increase the probability of retrieving this volume.  
Preliminary in vivo studies determined the approximate cell number necessary to have a 
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therapeutic effect within one or two days of implantation, leading to an encapsulation 
density of 1.0x107 cells/ml.  The lower cell density of either study was likely exacerbated 
in vivo due to the dispersion of microencapsulated beads within the intraperitoneal cavity.  
High cell densities have been shown to significantly increase insulin secretion in beta cell 
lines, relative to low cell densities, due to the change in cell-cell signaling (La Flamme et 
al. 2007; Luther et al. 2005).  Higher cell density encapsulations have also been shown to 
retain cell viability and function better during conventional freezing (Murua et al. 2009).  
This may also be the case for vitrification.  Vitrification of a low cell density 
encapsulation may result in a low viable cell density that is slow to recover and is too low 
to have a therapeutic effect, especially when implanted in the intraperitoneal cavity. 
Upon explantation, biomaterial assessment revealed that APA beads incurred 
damage and host-cell attachment while in vivo.  Neither of these phenomena appear to 
correlate to the test group, whether preserved or fresh.  Additionally, cell death does not 
appear to be due to host-cell attachment or compromised bead integrity.  This is likely 
due to the short time frame of the experiment.  The host-cell attachment that is seen may 
be truncated due to the time in vivo and would likely increase if the experiment was 
lengthened.  Bead integrity is critical to the long-term success of an implant as it provides 
a level of immunoprotection.  However, unencapsulated allogeneic islets can last eight 
days in vivo (Vergani et al. 2010).  As it is clear that the matrix damage occurred during 
the in vivo period, it is reasonable that the damaged beads maintained viability 
comparable to that of intact beads upon explantation.  The in vivo use of APA beads is 
widespread and has resulted in conflicting reports, specifically regarding the immune 
response to the beads and specific encapsulation parameters (Orive et al. 2006).  Despite 
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the variability in the explanted biomaterial, which has also been noted by other groups 
(Safley et al. 2008), it is clear that the ice formation that occurs during conventional 
freezing does not compromise the biomaterial integrity enough to result in poor in vivo 
performance.  The ice damage that the alginate matrix incurs during conventional 
freezing (Mukherjee et al. 2005) may not compromise the semi-permeable membrane, 
overall morphology or strength of the bead (Murua et al. 2009).    
The insulin secretory function of explanted beads was also variable, especially for 
the fresh and conventionally frozen beads, but still revealed statistical differences.  All 
preserved beads secreted significantly less than fresh on an explanted volume basis.  
Although not statistically significant, this also appeared to be the trend in sub-therapeutic 
studies.  This would be expected for the poor-performing vitrified groups.  The reason for 
the poor performance of explanted conventionally frozen beads is more difficult to 
ascertain.  Although many mice with conventionally frozen implants received 
tetracycline, further review of the data reveals that many of the explants that were 
exposed to tetracycline also secreted more insulin upon explantation than those that did 
not.  Tetracycline was also administered to several mice implanted with fresh beads.  It is 
unlikely that tetracycline is the cause of the lower insulin secretion seen for explanted 
conventionally frozen beads.  In spite of the lower insulin secretion post-explantation, 
conventionally frozen beads exhibit in vivo efficacy comparable to fresh beads.  This 
suggests that there is a range of viable implanted cell number that will have a therapeutic 
effect in vivo.  Conventionally frozen beads may be on the lower end of this range.  All of 
these results were calculated on a per volume basis as the beads cannot easily be 
dissolved.  To measure volumes as accurately as possible, an attempt was made to use 
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beads with minimal or no host-cell attachment.  This may have contributed to the 
variations in insulin secretion results.     
6.5 Conclusions 
Preservation is a critical step in bringing a tissue-engineered construct from the 
benchtop to the clinic.  Of the two main types of cryopreservation, vitrification is often 
considered to be the most promising due to the elimination of ice formation.  These 
studies investigated the cryopreservation of a widely used encapsulated cell system.  
Although previous studies indicate that ice damage may occur in the alginate matrix 
during conventional freezing, this damage appears to be negligible in the experimental, 
therapeutic in vivo system.  Conventionally frozen APA beads perform comparably to 
fresh while vitrified beads perform significantly worse.  Additionally, biomaterial 
assessment upon explantation indicates that all groups experience similar damage and 
host-cell attachment during two weeks in vivo.  It has been shown that ice damage is 
detrimental when considering constructs or natural tissues that serve an important 
mechanical function (Schenke-Layland et al. 2007), but this does not appear to be the 
case for an encapsulated cell system that primarily serves as a physical barrier for 





CONCLUSIONS AND FUTURE DIRECTIONS 
7.1 Conclusions 
The field of Tissue Engineering continues to grow rapidly through the use of 
novel biomaterials and the incorporation of a variety of cell types, including stem cells.  
Unfortunately, there remains a gap in the knowledge of preservation techniques for most 
of these constructs.  In this thesis, we have approached the preservation of one of the 
most commonly used tissue-engineered constructs, encapsulated cells.  CPA addition and 
removal protocols for vitrification were rationally designed using an expanded 
mathematical model.  In order to better understand the effects of cryopreservation on an 
encapsulated cell system, the biomaterial and cellular function were evaluated in vitro 
and in vivo for the two main types of cryopreservation: conventional freezing and 
vitrification.  This thesis has contributed to the field of cryopreservation and tissue 
engineering by systematically comparing the effects of these two types of preservation on 
one of the most commonly used technologies, cell encapsulation. 
In the first part of the thesis, the previously described mathematical model 
(Mukherjee et al. 2008) was expanded to incorporate heat transfer as well as cytotoxicity 
due to CPA exposure.  Cytotoxicity kinetics were determined experimentally and are 
reported in Chapter 3.  These results indicate that for the βTC-tet cell line, the CPA 
toxicity is contingent upon the time and temperature of exposure, CPA identity and 
concentration as well as the cell type and, more specifically, the metabolic activity of the 
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cells.  Additionally, the use of CPA cocktails to minimize the toxicity of the overall 
solution may not be as effective as previously thought.  Our results indicate that the 
addition of non-permeating solutes may serve to increase the intracellular concentration 
of permeating CPAs which increases the toxicity experienced by the cells.  These 
cytotoxicity results were incorporated into the expanded mathematical model for the 
design of CPA addition and removal protocols (Chapter 4).   
The previously described mathematical model described the mass transfer of 
CPAs through the matrix of the bead and the subsequent permeability of these CPAs 
through the cell membrane.  This allowed the design of addition and removal protocols 
that maintained cell osmotic excursions within a tolerable range.  This has been validated 
experimentally (Mukherjee et al. 2007).  The incorporation of heat transfer and a 
cytotoxicity equation based on experiment allowed for more insight into the design of 
addition and removal protocols.  Simulations indicate that, for the βTC-tet cell line, the 
temperature of CPA exposure is the most critical parameter.  Mathematical simulations 
were also done for a more recalcitrant tissue, articular cartilage.  These simulations also 
indicate that the most critical parameter for successful vitrification of a tissue is the 
temperature of exposure.  For this large construct, temperature of removal is also critical.  
Overexposure also leads to a decrease in viable cell number.  For successful vitrification, 
it is critical to ensure full equilibration throughout the sample while minimizing the cells’ 
overexposure to CPAs.  A mathematical model, such as this one, is widely applicable for 
the design of appropriate addition and removal protocols. 
The second part of the thesis was designed to address the two types of 
cryopreservation and their effects on an encapsulated cell system.  Chapter 5 focuses on 
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the in vitro evaluation of the biomaterial component and cellular component after 
preservation.  The function of the alginate/poly-L-lysine/alginate (APA) bead is to 
provide a physical barrier between the implanted cells and the host cells that play a role 
in the immune protection of the implant.  In vitro results revealed no significant 
differences in the biomaterial although occasional instances of damage to the alginate 
matrix, likely due to ice formation, were seen for conventionally frozen beads.  
Additionally, post-thaw viability and insulin secretion were similar for all groups, 
preserved or fresh.  A transient increase in basal insulin secretion was seen for beads 
vitrified using P6 although this difference may not affect the in vivo performance.  In 
vitro studies indicated that APA beads can be successfully preserved by conventional 
freezing or vitrification.  These results also suggested that preserved beads would 
perform similarly to fresh beads when implanted in vivo.  It remained unclear whether 
possible ice damage to the alginate matrix, seen occasionally in conventionally frozen 
beads, would affect the inflammatory immune response towards implanted beads.  
Despite the similarities seen in vitro, the in vivo results, as reported in Chapter 6, indicate 
significant differences in the performance of conventionally frozen and vitrified beads.  
Both vitrified groups showed less success in reverting streptozotocin-induced diabetic 
mice to a normoglycemic range.  Additionally, one of the vitrified groups took 
significantly longer to revert diabetes than fresh or conventionally frozen.  Explant 
assessment indicated that the ice formation that occurs in conventional freezing does not 
have a noticeable effect on the in vivo response to an APA bead.  The encapsulated APA 
system is very similar to a cell suspension and, likely due to this, it appears that 
conventional freezing is the better method of preservation for this system. 
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This thesis utilized rational design of CPA addition and removal for an 
encapsulated cell system and determined the effects of both vitrification, or ice-free 
cryopreservation, and conventional freezing on the in vitro and in vivo performance of the 
system.  The described mathematical model can be used to design addition and removal 
protocols and can be used for a range of natural tissues or tissue-engineered constructs.  
More generally, this thesis indicates the need for systematic assessment of conventional 
freezing and vitrification for the preservation of each tissue or tissue-engineered 
construct.  Although vitrification is often used specifically to eliminate ice formation and 
ice damage, it can be more technically complex than conventional freezing.  Therefore, 
with the long-term goal of clinical relevance, it is important to determine whether any 
benefits of vitrification outweigh the difficulties associated with its complexity.  For the 
investigated system, conventional freezing appears to be sufficient and requires less 
technical expertise.   
7.2 Future Directions 
7.2.1 Fundamental Cryopreservation Work 
In the field of cryobiology, significant work has been done to address the 
fundamental understanding of conventional freezing.  This understanding has been 
critical to the progress that has been made in the conventional freezing of different cell 
types and systems.  Currently, most vitrification literature focuses on the application of 
vitrification in the preservation of larger tissues or constructs.  Different groups have 
proposed the use of novel CPA cocktails (Agudelo et al. 2009), but there does not appear 
to be a systematic method that is used in the design of these cocktails.  To systematically 
assess and then design CPA cocktails, two properties must be determined: the glass-
119 
 
forming ability of the solution and the cytotoxicity.  CPA cytotoxicity is currently one of 
the most critical challenges for successful vitrification (Fahy 2010).  The CPA 
concentration necessary is determined based on its glass-forming ability.  Differential 
scanning calorimetry (DSC) can be used to determine the glass-transition temperature as 
well as the critical cooling and warming rates for a solution.  The use of different 
additives or non-permeating CPAs and different mixtures of permeating CPAs can be 
systematically evaluated for glass-forming ability and cytotoxicity.  This will allow for a 
better understanding of the different CPAs and their use in cocktails.  It is currently 
unclear how CPAs may interact with each other and how this will affect the glass-
forming ability of the solution and its overall cytotoxicity.  The issue of cryoprotectant 
toxicity neutralization is clearly important (Fahy 2010), and these studies would add 
significant insight to this theory.  They may also lead to better design of CPA cocktails 
for the vitrification of recalcitrant tissues.    
7.2.2 Mathematical Modeling 
A previously described mathematical model has been expanded in this thesis so 
that vitrification CPA addition and removal protocols can be systematically designed and 
better understood.  This model focuses on a relatively simple geometry with 
homogeneous cell distribution and biomaterial properties.  As the field of Tissue 
Engineering continues to grow, the constructs that are developed will become more 
complex.  This has already occurred for the tissue-engineered pancreatic substitute.  
Researchers are investigating the use of prevascularized beds (Pileggi et al. 2006), seeded 
endothelial cells (Jay et al. 2010) or novel heterogeneous biomaterials (Mason and 
Mahoney 2010) to address the issue of vascularization which is critical for encapsulated 
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islets.  Newly developed constructs will require cryopreservation.  The current 
mathematical model could easily be changed to reflect some of the complexities that may 
be incorporated in new constructs.  The use of anisotropic materials would affect the 
mass transfer through the matrix.  Anisotropy occurs in natural tissues also, such as 
mature bovine articular cartilage where cell density and distribution vary throughout 
(Jadin et al. 2005).  More complex constructs may also incorporate different cell types 
which exhibit different permeability constants and different levels of tolerance for 
osmotic excursions.  The modeling of cell-clusters, such as islets, would require 
additional considerations.  In a cell cluster, such as an islet, the mechanism of CPA mass 
transfer would likely be different.  Mass transfer could occur through microvasculature.  
Additionally, if no vasculature is present, mass transfer could occur through direct 
contact of cell membranes and would rely upon the permeability of these membranes.  
Incorporation of any of these complexities in the mathematical model would also make it 
more easily applicable to natural tissues.     
7.2.3 Cryopreservation of Tissue-Engineered Constructs 
The main advantage of vitrification is that it eliminates ice formation.  Ice 
formation may not be critical for the preservation of an encapsulated cell system due to 
its size, high diffusivity and the suspended nature of the cells.  It has been suggested that 
vitrification and conventional freezing may perform comparably when working with 
small tissue structures (Brockbank and Taylor 2007).  Due to the complexity of the 
vitrification process, it is important to ensure that vitrification is necessary by comparing 
the effects of both types of cryopreservation on a specific construct.  Encapsulated islets 
have been used increasingly in the laboratory setting for the treatment of diabetes.  
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Determining the best method of cryopreservation of this system would be the most direct 
extension of this thesis.  Iwata’s research group in Japan has utilized a new vitrification 
solution for the vitrification of encapsulated islets.  They indicate that vitrified islets were 
able to revert diabetes in mice, although this required twice the number of encapsulated 
islets as compared to unpreserved islets (Agudelo et al. 2009).  This indicates that these 
islets may have incurred damage during the vitrification process, possibly due to 
unsuccessful vitrification at the core of the islets.  The cryosubstitution technique, in 
which an organic solvent is introduced at the temperature of storage and dissolves any ice 
that has formed, can be used to visualize ice formation.  This method could be used to 
corroborate the successful vitrification of the islets.  The mathematical model, as 
explained above, could be changed to reflect the mass transfer of CPAs through the islets.  
Properly designed protocols would minimize the chance of ice formation.  Although the 
cryopreservation of free and encapsulated islets has been shown in literature, a systematic 
comparison of the two methods is necessary.  It remains to be seen whether conventional 
freezing will be sufficient for the preservation of most encapsulated systems.  
Within the context of a load-bearing construct or a construct that primarily serves 
a mechanical function, the elimination of ice may be critical to the performance of the 
construct.  Ice formation can lead to a loss of mechanical integrity and important 
physiological properties, such as viscoelasticity (Thakrar et al. 2006) or contractility 
(Dahl et al. 2006).  Future studies of the effects of cryopreservation should focus on more 
complex tissues or tissue-engineered constructs.  Adherent cells seeded into a 
hydroxyapatite matrix require that these cells remain attached for proper function, but 
conventional freezing has been shown to cause detachment (Liu et al. 2006).  It is 
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systems such as these, where ice formation is particularly damaging, that should be 
investigated.   
Additionally, it is critical that studies on the effects of cryopreservation look 
deeper into the mechanisms of damage.  Many studies have addressed the preservation of 
hepatocytes, a commonly used cell type, but few have investigated the reason for 
nonattachment after conventional freezing (Terry et al. 2007).  Understanding of the 
molecular mechanisms behind different types of cryodamage will allow better design of 
procedures and will lead to more successful cryopreservation methods. 




SUPPLEMENTARY DATA OF CYTOTOXICITY EFFECTS OF 
CRYOPROTECTANTS AS SINGLE-COMPONENT AND 
COCKTAIL VITRIFICATION SOLUTIONS 
 This appendix presents supplementary data for CHAPTER 3.  The data presented 
here exhibit the same trends as those shown in CHAPTER 3.  Viable cell number was 
determined using alamarBlue™ which measures the metabolic activity of the cells.  Cell 
viability as determined by Trypan Blue was shown in Chapter 3 as this is a more direct 
measure of cell toxicity.  The trends for alamarBlue™ results are very similar to those 






Figure A.1. Viable Cell Number vs. time for DMSO for 2M ( ), 4M ( ) and 
6M ( ) at 4°C or room temperature (empty) for encapsulated βTC-tet cells.  
Viable cell number determined by alamarBlue™, normalized to untreated control.  












Table A.1. Pairwise Comparison of Single-Component Cytotoxicity Kinetics.  p<0.05 for 
corresponding letters (e.g. p<0.05 when comparing 4M and 6M DMSO at 30 minutes at 






Incubation at 4°C Incubation at 25°C 
4 min 10 min 15 min 30 min 4 min 10 min 15 min 30 min 
2M DMSO O - N L - K I,J G,H 
4M DMSO A,P B C D,M A B,K C,I D,G 
6M DMSO E,O,P,Q   F,N L,M,Q E - F,J H 
                  
2M PD R,q,r,s s p S,n,o R,f d b,c S,Y,Z 
4M PD U,q V W,p T,X,n U,g,i,j V,e,k,l W,b,i,k,m 
T,X,Y,a,
j,l,m
6M PD r - - o f,g,h d,e b,c Z,a,h 
Figure A.2. Viable Cell Number vs. time for PD for 2M ( ), 4M ( ) and 6M ( ) 
at 4°C or room temperature (empty) for encapsulated βTC-tet cells.  Viable cell number 
determined by alamarBlue™, normalized to untreated control.  Error bars not shown for 









Figure A.3. Viable Cell Number vs. time for P6 ( ) and DPS ( ) at 4°C or room 
temperature (empty) for encapsulated βTC-tet cells. Viable cell number normalized to 
untreated control. Error bars indicate standard deviations, n=3.  #, *,† indicate p<0.05 when 
comparing groups. Also, p<0.05 comparing P6 at RT to all other groups at each time point.   
Figure A.4. Viable Cell Number for 3M DMSO, 3M PD and DP6 for encapsulated βTC-
tet cells (solids) compared to encapsulated HepG2 cells (stripes) for an incubation period 
of 15 minutes.  Viable cell number normalized to untreated control.  Error bars indicate 




MATLAB® CODE FOR MATHEMATICAL MODEL 
B.1 Introduction 
 This appendix provides the Matlab® code that makes up the entirety of the 
mathematical model described in CHAPTER 4.  It is shown for the alginate bead.  The 
model consists of a main program which passes variables to sub-programs.  The sub-
programs calculate the concentration and temperature profiles, convert concentration 
from molarity to osmolarity, calculate the water volume and solutes within cells at 
different positions throughout the bead and calculate cytotoxicity as a function of time for 
cells at different positions throughout the bead.   
B.2 Main Program 
%********************************************************************** 
% Institution:   Georgia Institute of Technology 
% Dept:    School of Chemical & Biomolecular Engineering 
% PI:            A. Sambanis 
% Title:         Developing Cryoprotectant Addition-Removal Protocols Using a  
%  2-parameter Model for βTC-tet cells 
% Authors:      Alison Lawson, Indra Neil Mukherjee and Yang Li 
%********************************************************************** 
% Clear all global variables needed for simulations  
clear; 
    global timestep; global Ra; global rstep; global R; 
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    %CPA information 
    mwdmso=78.13;        % molecular weight DMSO [g/mol] 
    ddmso=1.11;                % density DMSO [g/cm3] 
    mwpd=76.09;                % molecular weight Propanediol [g/mol] 
    dpd=1.04;   % density Propanediol [g/cm3] (PD) 
    mwfm=45.04;  % molecular weight formamide [g/mol] 
    dfm=1.133;   % density of formamide [g/cm3] (FM) 
    mwsucrose=342.3;  % molecular weight of sucrose [g/mol] 
     
% Experimentally determined density of final solutions for conversion  
% between osmolality and osmolarity 
    dDPSA3=1.098;              %density of final solution of DPS 
    dP4A4=1.027;               %density of final solution of P6 
    dsoln=dP4A4;               %!!!Define Solution 
 
% CELLS = βTC tet cells  
% Volume information: Vo, Vb determined experimentally by Dr. Mukherjee 
    Vo=750;                  % isotonic cell volume [um3] 
    vs=mwdmso/ddmso*1e12;  % partial molar solute volume [um3/mol] 
    Vb=0.184*Vo;               % inactive cell volume [um3] 
    Vwo=Vo-Vb;                 % initial vol. of intracellular H2O [um3] 
    A = 4.836*Vo^(2/3);        % surface area of cell [um^2] 
    Mino=0.3;                 % initial intracellular non-perm solute C [osmolarity]    
128 
 
    % Universal gas constant values 
     R = 8.21e13;               % universal gas constant [um3*atm/mol*K] 
     Rcal = 1.98721;           % universal gas constant [cal/mol*K] 
% Miscellaneous Definitions     
    C_EC=0.3*ones(100,1);     % Account for extracellular osmolality  
% due to EuroCollins [osmolality] 
    n = 2;                      % specify the number of CPAs in solution 
    Ra =250;                   % Radius of the construct (um) 
    rstep=100;                 % Number of different radial positions, with lower  
% number indicating position toward center of bead   
    B_CPA{1,1} = 0.0843;      % DMSO virial coefficient 
    B_CPA{1,2} = 0.0576;      % PD virial coefficient 
    B_CPA{1,3} = -0.0306;     % FM virial coefficient 
% Diffusivity data 
    alpha=1.4586e11;           % thermal diffusivity of water [um^2/s] 
 % Assume Arrhenius Equation for Diffusivity dependence on T     
    Ao = [0.593e3 0.293e3 0.893e3]; % Pre-exponential Factor for DMSO, PD &  
% FM [um2/s] 
    Ao_S = 0.178e3;   % Pre-exponential Factor for sucrose [um2/s] 
    Eact = [1.895e17 3.67e17 1.359e17]; 
% Activation Energy for DMSO, PD &  
% FM [um3*atm/mol]  
    Ea_S = 4.198e17;   % Act. Energy for Sucrose [um3*atm/mol] 
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    % Define CPA Addition protocol 
   tinitial = 298;               % Initial temperature of bead (K) 
   addsteps=4;                   % Number of addition steps 
   cpaconcadd=zeros(3,addsteps);  % Create array 
   cpaconcadd(1,:) = [0.5 1 1 1];     % Conc. of DMSO for each step [M] 
   cpaconcadd(2,:) = [1 2 4 5];       % Conc. of PD for each step [M] 
   cpaconcadd(3,:) = [0 0 0 0];       % Conc. of FM for each step [M] 
   tExtAdd = [298 298 298 298]; 
    Addition_sucrose = [0 0 0 0.3384]; % Conc. of sucrose for each step [M] 
   timeadd=[60*3 60*3 60*3 60*3];    % exposure time for each step [s] 
    
% Define CPA Removal protocol 
   removesteps = 4;            % Number of removal steps 
   cpaconcremove=zeros(3,removesteps);     % Create array 
   cpaconcremove(1,:)= [0.75 0.5 0.25 0];     % Conc. of DMSO for each step [M] 
   cpaconcremove(2,:)= [4 2 1 0];     % Conc. of PD for each step [M] 
   cpaconcremove(3,:)= [0 0 0 0];     % Conc. of FM for each step [M] 
   tExtRem = [298 298 298 298];  % External T for each step [K] 
   removal_sucrose = [0.2 0.2 0 0];       % Conc. of sucrose for each step [M]                                 
   timeremoval=[60*2 60*2 60*2 60*5];    % exposure time for each step [s] 
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 % Compile Addition & Removal 
   steps = addsteps + removesteps; 
   cpaconc = [cpaconcadd cpaconcremove]; 
   sucroseconc= [Addition_sucrose removal_sucrose]; 
   tExt = [tExtAdd tExtRem];   %  External T [K] 
   Time_All =[timeadd timeremoval]; 
   sumsteps = steps * 100; 
   sumTime =sum(Time_All); 
   timestep=100;                    % Number of points for each step 
   Conc = zeros(1, rstep);   % Create array 
   Temp = ones(1, rstep)*tinitial;  % Create array 
   t2 = zeros(sumsteps,1); 
   maxrows = 100*steps;    % Pre-allocate Profile arrays                       
   cols = 10; 
   Profileat50 = zeros(maxrows, cols); 
   Profileat0 = zeros(maxrows, cols); 
   ProfileatR = zeros(maxrows, cols); 
   loc = [1 100; 101 200; 201 300; 301 400; 401 500; 501 600; 601  
700; 701 800; 801 900; 901 1000];          






% CPA ADDITION 
   for j=1:steps;                   % For loop of addition steps 
         tfinal=sum(Time_All(1:j)); 
         tstart=sum(Time_All(1:(j-1))); 
% First determine conc. and T profiles in bead 
            if j==1    % 1st step utilizes initial values 
               Ci1 = zeros(1,100);  
               Ci2 = zeros(1,100); 
               Ci3 = zeros(1,100); 
               CiS = zeros(1,100);   % Initially no CPAs present in bead 
               ti = ones(1,100);      % Initially no T-gradient in bead 
               Ti = tinitial*ti;  
               cext = cpaconc(:,j); 
               cextS = sucroseconc(j); 
               text = tExt(j); 
               addtime = Time_All(j); 
   [Conc_1 Conc_2 Conc_3 Conc_S Temp] = pdenewmh_total(alpha, Ti, Ci1,  
     Ci2, Ci3, CiS, cext, cextS, text, Ao, Eact, Ao_S, Ea_S, addtime);  
% Pass diffusivity info, C &T profile in bead & external C to mass/heat pde: p.142  
% Return concentration profile of CPAs and temperature profile in bead  
 % Input conc. and T profile into cell perm. Eqns at r=0, 50, 100 
            y0 = [Vwo; 0; 0; 0];     % Define initial values: Vw=Vwo, Ns=0 
               tspan = linspace(tstart, tfinal, timestep); 
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               t2(loc(j,1):loc(j,2)) = tspan; 
           % At r=0 
               C_1 = Conc_1(:,1); 
               C_2 = Conc_2(:,1); 
               C_3 = Conc_3(:,1); 
               C_S = Conc_S(:,1); 
               C_tot = C_1+C_2+C_3+C_S+C_EC; 
               T = Temp(:,1); 
          % Convert Molarity to Osmolarity: p. 144               
               [Osm_1 Osm_2 Osm_3 Osm_S] = conversion (C_1,C_2, 
                        C_3,C_S,mwdmso,mwpd,mwfm,mwsucrose,dsoln); 
                Osm_tot = Osm_1+Osm_2+Osm_3+Osm_S+.3; 
          % Pass osmolarities to permeability equations: p.146 
               [t,y] =ode15s(@(t,y) Perm(t,y,tspan,A,R,T,Osm_tot,... 
                          Osm_1,Osm_2,Osm_3,Mino,Rcal), tspan, y0); 
               Ntot = y(:,2)+y(:,3)+y(:,4); 
               Vnorm = 1/Vwo*(y(:,1)+Vb);   % Normalized cell volume 
               yconv = [y(:,2)*1e15./y(:,1) y(:,3)*1e15./y(:,1) y(:,4)*1e15/y(:,1)]; 
  % Convert from moles/um3 to M 
% Store all profiles 
               Profileat0(loc(j,1):loc(j,2),1) = Conc_1(:,1); 
               Profileat0(loc(j,1):loc(j,2),2) = Conc_2(:,1); 
               Profileat0(loc(j,1):loc(j,2),3) = Conc_3(:,1); 
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               Profileat0(loc(j,1):loc(j,2),4) = Conc_S(:,1); 
               Profileat0(loc(j,1):loc(j,2),5) = Temp(:,1);  
               Profileat0(loc(j,1):loc(j,2),6) = Vnorm; 
               Profileat0(loc(j,1):loc(j,2),7) = yconv(:,1); 
               Profileat0(loc(j,1):loc(j,2),8) = yconv(:,2); 
               Profileat0(loc(j,1):loc(j,2),9) = yconv(:,3); 
               Profileat0(loc(j,1):loc(j,2),10) = Ntot; 
               y0at0 = [y(100,1); y(100,2); y(100,3); y(100,4)]; 
 % REPEAT FOR DIFFERENT POSITIONS                            
           % At r approx = 125 um from center (123.7) 
               C_1 = Conc_1(:,50); 
               C_2 = Conc_2(:,50); 
               C_3 = Conc_3(:,50); 
               C_S = Conc_S(:,50); 
               C_tot = C_1+C_2+C_3+C_S+C_EC; 
               T = Temp(:,50); 
% Convert Molarity to Osmolarity: p. 144              
               [Osm_1 Osm_2 Osm_3 Osm_S] = conversion (C_1,C_2,... 
                            C_3,C_S,mwdmso,mwpd,mwfm,mwsucrose,dsoln); 
               Osm_tot = Osm_1+Osm_2+Osm_3+Osm_S+.3; 
% Pass osmolarities to permeability equations: p. 146              
               [t,y] =ode15s(@(t,y)Perm(t,y,tspan,A,R,T,Osm_tot,... 
                          Osm_1,Osm_2,Osm_3,Mino,Rcal), tspan, y0); 
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               Ntot = y(:,2)+y(:,3)+y(:,4); 
               Vnorm = 1/Vwo*y(:,1);   % Normalized cell volume 
               yconv = [y(:,2)*1e15./y(:,1) y(:,3)*1e15./y(:,1) y(:,4)*1e15/y(:,1)]; 
  % Convert from moles/um3 to M 
% Store all profiles                
  Profileat50(loc(j,1):loc(j,2),1) = Conc_1(:,50); 
               Profileat50(loc(j,1):loc(j,2),2) = Conc_2(:,50); 
               Profileat50(loc(j,1):loc(j,2),3) = Conc_3(:,50); 
               Profileat50(loc(j,1):loc(j,2),4) = Conc_S(:,50); 
               Profileat50(loc(j,1):loc(j,2),5) = Temp(:,50);  
               Profileat50(loc(j,1):loc(j,2),6) = Vnorm; 
               Profileat50(loc(j,1):loc(j,2),7) = yconv(:,1); 
               Profileat50(loc(j,1):loc(j,2),8) = yconv(:,2); 
               Profileat50(loc(j,1):loc(j,2),9) = yconv(:,3); 
               Profileat50(loc(j,1):loc(j,2),10) = Ntot; 
               y0at50 = [y(100,1); y(100,2); y(100,3); y(100,4)];  
% At r=R 
               C_1 = Conc_1(:,100); 
               C_2 = Conc_2(:,100); 
               C_3 = Conc_3(:,100); 
               C_S = Conc_S(:,100); 
               C_tot = C_1+C_2+C_3+C_S+C_EC; 
               T = Temp(:,100); 
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          % Convert Molarity to Osmolarity: p. 144                             
               [Osm_1 Osm_2 Osm_3 Osm_S] = conversion (C_1,C_2,... 
                            C_3,C_S,mwdmso,mwpd,mwfm,mwsucrose,dsoln); 
                Osm_tot = Osm_1+Osm_2+Osm_3+Osm_S+.3; 
          % Pass osmolarities to permeability equations: p. 146               
               [t,y] =ode15s(@(t,y)Perm(t,y,tspan,A,R,T,Osm_tot,... 
                          Osm_1,Osm_2,Osm_3,Mino,Rcal), tspan, y0); 
                 Ntot = y(:,2)+y(:,3)+y(:,4); 
                 Vnorm = 1/Vwo*(y(:,1)+Vb);       % Normalized cell volume 
                 yconv = [y(:,2)*1e15./y(:,1) y(:,3)*1e15./y(:,1) y(:,4)*1e15/y(:,1)]; 
 % Convert from moles/um3 to M 
% Store all profiles                
               ProfileatR(loc(j,1):loc(j,2),1) = Conc_1(:,99); 
               ProfileatR(loc(j,1):loc(j,2),2) = Conc_2(:,99); 
               ProfileatR(loc(j,1):loc(j,2),3) = Conc_3(:,99); 
               ProfileatR(loc(j,1):loc(j,2),4) = Conc_S(:,99); 
               ProfileatR(loc(j,1):loc(j,2),5) = Temp(:,99);  
               ProfileatR(loc(j,1):loc(j,2),6) = Vnorm; 
               ProfileatR(loc(j,1):loc(j,2),7) = yconv(:,1); 
               ProfileatR(loc(j,1):loc(j,2),8) = yconv(:,2); 
               ProfileatR(loc(j,1):loc(j,2),9) = yconv(:,3); 
               ProfileatR(loc(j,1):loc(j,2),10) = Ntot; 
               y0atR = [y(100,1); y(100,2); y(100,3); y(100,4)]; 
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           else   % other steps utilize C & T profile from previous step 
               r = linspace(0, Ra, rstep); 
               Ci1 = Conc_1(100,:)'; 
               Ci2 = Conc_2(100,:); 
               Ci3 = Conc_3(100,:); 
               CiS = Conc_S(100,:); 
               Ti = Temp(100,:); 
               cext = cpaconc(:,j); 
               cextS = sucroseconc(j); 
               text = tExt(j); 
               addtime = Time_All(j); 
  [Conc_1 Conc_2 Conc_3 Conc_S Temp] =    
               pdenewmh_total(alpha, Ti, Ci1, Ci2, Ci3, CiS, cext,  
               cextS, text, Ao, Eact, Ao_S, Ea_S, addtime); 
% Pass diffusivity info, C &T profile in bead & external C to mass/heat pde: p. 142  
               tspan = linspace(tstart, tfinal, timestep); 
               t2(loc(j,1):loc(j,2)) = tspan; 
% At r=0 
               C_1 = Conc_1(:,1); 
               C_2 = Conc_2(:,1); 
               C_3 = Conc_3(:,1); 
               C_S = Conc_S(:,1); 
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               C_tot = C_1+C_2+C_3+C_S+C_EC; 
               T = Temp(:,1); 
               y0 = y0at0; 
% Convert Molarity to Osmolarity: p. 144                                          
               [Osm_1 Osm_2 Osm_3 Osm_S] = conversion (C_1,C_2,... 
                            C_3,C_S,mwdmso,mwpd,mwfm,mwsucrose,dsoln); 
               Osm_tot = Osm_1+Osm_2+Osm_3+Osm_S+.3; 
 % Pass osmolarities to permeability equations: p. 146                             
               [t,y] =ode15s(@(t,y) Perm(t,y,tspan,A,R,T,Osm_tot,... 
                          Osm_1,Osm_2,Osm_3,Mino,Rcal), tspan, y0); 
               Ntot = y(:,2)+y(:,3)+y(:,4); 
               Vnorm = 1/Vwo*(y(:,1)+Vb);       % Normalized cell volume 
               yconv = [y(:,2)*1e15./y(:,1) y(:,3)*1e15./y(:,1) y(:,4)*1e15/y(:,1)]; 
% Convert from moles/um3 to M 
% Store all profiles                
               Profileat0(loc(j,1):loc(j,2),1) = Conc_1(:,1); 
               Profileat0(loc(j,1):loc(j,2),2) = Conc_2(:,1); 
               Profileat0(loc(j,1):loc(j,2),3) = Conc_3(:,1); 
               Profileat0(loc(j,1):loc(j,2),4) = Conc_S(:,1); 
               Profileat0(loc(j,1):loc(j,2),5) = Temp(:,1);  
               Profileat0(loc(j,1):loc(j,2),6) = Vnorm; 
               Profileat0(loc(j,1):loc(j,2),7) = yconv(:,1); 
               Profileat0(loc(j,1):loc(j,2),8) = yconv(:,2); 
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               Profileat0(loc(j,1):loc(j,2),9) = yconv(:,3); 
               Profileat0(loc(j,1):loc(j,2),10) = Ntot; 
               y0at0 = [y(100,1); y(100,2); y(100,3); y(100,4)]; 
 % At r approx = 125 um from center (123.7) 
               C_1 = Conc_1(:,50); 
               C_2 = Conc_2(:,50); 
               C_3 = Conc_3(:,50); 
               C_S = Conc_S(:,50); 
               C_tot = C_1+C_2+C_3+C_S+C_EC; 
               T = Temp(:,50); 
               y0 = y0at50; 
 % Convert Molarity to Osmolarity: p. 144                                                    
               [Osm_1 Osm_2 Osm_3 Osm_S] = conversion (C_1,C_2,... 
                            C_3,C_S,mwdmso,mwpd,mwfm,mwsucrose,dsoln); 
               Osm_tot = Osm_1+Osm_2+Osm_3+Osm_S+.3; 
 % Pass osmolarities to permeability equations: p. 146                                           
               [t,y] =ode15s(@(t,y) Perm(t,y,tspan,A,R,T,Osm_tot,... 
                          Osm_1,Osm_2,Osm_3,Mino,Rcal), tspan, y0); 
               Ntot = y(:,2)+y(:,3)+y(:,4); 
               Vnorm = 1/Vwo*(y(:,1)+Vb);   % Normalized cell volume 
               yconv = [y(:,2)*1e15./y(:,1) y(:,3)*1e15./y(:,1) y(:,4)*1e15/y(:,1)]; 
% Convert from moles/um3 to M 
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% Store all profiles                
               Profileat50(loc(j,1):loc(j,2),1) = Conc_1(:,50);                                    
               Profileat50(loc(j,1):loc(j,2),2) = Conc_2(:,50); 
               Profileat50(loc(j,1):loc(j,2),3) = Conc_3(:,50); 
               Profileat50(loc(j,1):loc(j,2),4) = Conc_S(:,50); 
               Profileat50(loc(j,1):loc(j,2),5) = Temp(:,50);  
               Profileat50(loc(j,1):loc(j,2),6) = Vnorm; 
               Profileat50(loc(j,1):loc(j,2),7) = yconv(:,1); 
               Profileat50(loc(j,1):loc(j,2),8) = yconv(:,2); 
               Profileat50(loc(j,1):loc(j,2),9) = yconv(:,3); 
               Profileat50(loc(j,1):loc(j,2),10) = Ntot; 
               y0at50 = [y(100,1); y(100,2); y(100,3); y(100,4)]; 
    % At r=R 
               C_1 = Conc_1(:,99); 
               C_2 = Conc_2(:,99); 
               C_3 = Conc_3(:,99); 
               C_S = Conc_S(:,99); 
               C_tot = C_1+C_2+C_3+C_S+C_EC; 
               T = Temp(:,99); 
               y0 = y0atR; 
   % Convert Molarity to Osmolarity: p. 144                                                     
               [Osm_1 Osm_2 Osm_3 Osm_S] = conversion (C_1,C_2,... 
                        C_3,C_S,mwdmso,mwpd,mwfm,mwsucrose,dsoln); 
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% Pass osmolarities to permeability equations: p. 146                                    
               Osm_tot = Osm_1+Osm_2+Osm_3+Osm_S+.3; 
               [t,y] =ode15s(@(t,y) Perm(t,y,tspan,A,R,T,Osm_tot,... 
                          Osm_1,Osm_2,Osm_3,Mino,Rcal), tspan, y0); 
               Ntot = y(:,2)+y(:,3)+y(:,4); 
               Vnorm = 1/Vwo*(y(:,1)+Vb);   % Normalized cell volume 
               yconv = [y(:,2)*1e15./y(:,1) y(:,3)*1e15./y(:,1) y(:,4)*1e15/y(:,1)]; 
% Convert from moles/um3 to M 
% Store all profiles                
               ProfileatR(loc(j,1):loc(j,2),1) = Conc_1(:,99); 
               ProfileatR(loc(j,1):loc(j,2),2) = Conc_2(:,99); 
               ProfileatR(loc(j,1):loc(j,2),3) = Conc_3(:,99); 
               ProfileatR(loc(j,1):loc(j,2),4) = Conc_S(:,99); 
               ProfileatR(loc(j,1):loc(j,2),5) = Temp(:,99);  
               ProfileatR(loc(j,1):loc(j,2),6) = Vnorm; 
               ProfileatR(loc(j,1):loc(j,2),7) = yconv(:,1); 
               ProfileatR(loc(j,1):loc(j,2),8) = yconv(:,2); 
               ProfileatR(loc(j,1):loc(j,2),9) = yconv(:,3); 
               ProfileatR(loc(j,1):loc(j,2),10) = Ntot; 
               y0atR = [y(100,1); y(100,2); y(100,3); y(100,4)]; 
                             
           end 
     end 
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% Pass profiles to cytotoxicity equation: p. 145  
            Profile=Profileat0; 
            [viability rate] = cytotoxicity(Profile,t2,sumsteps); 
            viabilityat0=viability; 
            rateat0=rate; 
             
            Profile=Profileat50; 
            [viability rate] = cytotoxicity(Profile,t2,sumsteps); 
            viabilityat50=viability; 
            rateat50=rate; 
             
            Profile=ProfileatR; 
            [viability rate] = cytotoxicity(Profile,t2,sumsteps); 
            viabilityatR=viability; 
            rateatR=rate; 
% Output profiles and cytotoxicity to Excel Spreadsheet  
xlswrite('Output.xls', Profileat0, 'Profile0', 'A1'); 
xlswrite('Output.xls', Profileat50, 'Profile50', 'A1'); 
xlswrite('Output.xls', ProfileatR, 'ProfileR', 'A1'); 
xlswrite('Output.xls', t2, 'time', 'A1'); 
xlswrite('Output.xls', viabilityat0, 'viability', 'A1'); 
xlswrite('Output.xls', viabilityat50, 'viability', 'B1'); 
xlswrite('Output.xls', viabilityatR, 'viability', 'C1'); 
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B.3 Mass & Heat Transfer Program 
m = 2;                                         % spherical geometry 
r = linspace(0, Ra, rstep);                    % create a row of radius values 
t = linspace(0, addtime, timestep);           % create a row of time values 
options = [];                             % use of options allows passing of additional variables 
 % Pass variables from main program 
sol = depe(m,@pdenewmhSpde,@pdenewmhSic,@pdenewmhSbc,r,t,options,alpha,Ti,... 
              Ci1,Ci2,Ci3,CiS,cext,cextS,text,Ao,Eact,Ao_S,Ea_S,addtime); 
Conc_1 = sol(:,:,1); 
Conc_2 = sol(:,:,2); 
Conc_3 = sol(:,:,3); 
Conc_S = sol(:,:,4); 
Temp = sol(:,:,5); 
 % Use pde solver to determine all concentration profiles and temperature profile 
function [c,f,s] = pdenewmhSpde(r,t,u,DuDx,alpha,Ti,Ci1,Ci2,Ci3,CiS,cext,... 
                    cextS,text,Ao,Eact,Ao_S,Ea_S,addtime) 
D_1 = 0.8*Ao(1)*exp(Eact(1)/R*(1/277-1/u(5))); 
D_2 = 0.8*Ao(2)*exp(Eact(2)/R*(1/277-1/u(5))); 
D_3 = 0.8*Ao(3)*exp(Eact(3)/R*(1/277-1/u(5))); 
D_S = 0.8*Ao_S*exp(Ea_S/R*(1/277-1/u(5))); 
c = [1/D_1; 1/D_2; 1/D_3; 1/D_S; 1/alpha]; 
f = [1; 1; 1; 1; 1] .* DuDx; 
s = [0; 0; 0; 0; 0]; 
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% Initial Conditions 
function u0 = pdenewmhSic(r,alpha,Ti,Ci1,Ci2,Ci3,CiS,cext,cextS,... 
    text,Ao,Eact,Ao_S,Ea_S,addtime) 
global Ra; global rstep; 
rspan = linspace(0, Ra, rstep); 
% Use interpolate to describe conc. and T profile.  For first step, all coeff = 0. 
C01 = interp1(rspan,Ci1,r); 
C02 = interp1(rspan,Ci2,r); 
C03 = interp1(rspan,Ci3,r); 
C0S = interp1(rspan,CiS,r); 
T0 = interp1(rspan,Ti,r); 
u0 = [C01; C02; C03; C0S; T0]; 
% Boundary Conditions 
function [pl,ql,pr,qr] = pdenewmhSbc(xl,ul,xr,ur,t,alpha,Ti,Ci1,Ci2,Ci3,... 
                            CiS,cext,cextS,text,Ao,Eact,Ao_S,Ea_S,addtime) 
pl = [0; 0; 0; 0; 0]; 
ql=[1;1;1;1;1]; 








B.4 Convert Molarity to Osmolarity 
function [Osm_1 Osm_2 Osm_3 Osm_S] = conversion(C_1,C_2,C_3,C_S,... 
    mwdmso,mwpd,mwfm,mwsucrose,dsoln) 
% Virial coefficients for CPAs [molal]^-1 
B_dmso = 0.108; 
B_pd = 0.039; 
B_fm = 0.108;     % use DMSO value 
B_sucrose = 0.125; 
 
% Determine ratio of L solution/kg solvent assuming volume additivity 
ratio_1 = 1./(dsoln-C_1.*mwdmso./1000); 
ratio_2 = 1./(dsoln-C_2.*mwpd./1000); 
ratio_3 = 1./(dsoln-C_3.*mwfm./1000); 
ratio_S = 1./(dsoln-C_S.*mwsucrose./1000); 
 
% Determine  L soln:kg solvent assuming mass additivity & density of final soln 
 
% Convert to Molality 
Mol_1 = C_1.*ratio_1; 
Mol_2 = C_2.*ratio_2; 
Mol_3 = C_3.*ratio_3; 




% Convert to Osmolality (osmol/kg solvent) 
Osmol_1 = Mol_1+B_dmso.*Mol_1.*Mol_1; 
Osmol_2 = Mol_2+B_pd.*Mol_2.*Mol_2; 
Osmol_3 = Mol_3+B_fm.*Mol_3.*Mol_3; 
Osmol_S = Mol_S+B_sucrose.*Mol_S.*Mol_S; 
 
% Convert to Osmolarity (osmol/L solution) using ratio 
Osm_1 = Osmol_1./ratio_1; 
Osm_2 = Osmol_2./ratio_2; 
Osm_3 = Osmol_3./ratio_3; 















B.5 Cell Permeability Program 
function dydt = Perm(t,y,tspan,A,R,T,Osm_tot,Osm_1,Osm_2,Osm_3,Mino,Rcal) 
 dydt = zeros(4,1); 
 T = interp1(tspan,T,t);    % Interpolate temperature profile 
Osm_tot = interp1(tspan,Osm_tot,t);  % Interpolate all osmolarity profiles 
Osm_1 = interp1(tspan,Osm_1,t);     
Osm_2 = interp1(tspan,Osm_2,t); 
Osm_3 = interp1(tspan,Osm_3,t); 
Ps1=4.73e-2*exp(14100/Rcal*(1/277-1./T));        % DMSO 
Ps2=5.81e-2*exp(14600/Rcal*(1/277-1./T));        % PD 
Ps3=5.27e-2*exp(14350/Rcal*(1/277-1./T));        % FM: avg of PD & DMSO 
Lp=6.67e-4*exp(15400/Rcal*(1/277-1./T)); 
 
dydt(1) = -Lp.*A*R.*T.*(Osm_tot/1e15-(Mino*612e-15+y(2)+y(3)+y(4))/y(1));      
      % Water flux into the cell: y(1)= Vw 
dydt(2) = A.*Ps1.*(Osm_1/1e15-y(2)/y(1));  % Solute flux into cell: y(2) = Ns DMSO 
dydt(3) = A.*Ps2.*(Osm_2/1e15-y(3)/y(1));  % Solute flux into cell for PD 
dydt(4) = A.*Ps3.*(Osm_3/1e15-y(4)/y(1));  % Solute flux into cell for FM 
 %Assumptions:    
% 1. Water and solutes do not interact with each other 
%  2. Ns for each component is unaffected by others (Each solute flux is only  
% affected by its own previous solute concentration: Mint or Cint(1) = Ns(1)/Vw 
% 3. Conc. of nonpermeating solute only effects external conc. for water flux   
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B.6 Cytotoxicity Program 
function [viability rate] = cytotoxicity(Profile,t2,sumsteps) 
% This version accounts for two CPAs: DMSO & PD 
parameters = [20000 124000; 4270 4930; 0.08 0.17];         
% parameters(i,1) for DMSO, parameters(i,2) for PD  
Totprof=Profile(:,1)+Profile(:,2)+Profile(:,3); 










 Sknot=.995;   % Initial guess for viable cell number 
  S0=Sknot; 
  x0=1; 
% Incrementally solve cytotoxicity equation for each time step using fzero function: 
    for n = 1:sumsteps; 
        if n==1; 
            bigA = 0; 
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            bigm = 0; 
            delt = t2(2)/60; 
       else 
            bigA = abs((A(n)+A(n-1))/2); 
            bigm = abs((m(n)+m(n-1))/2); 
            delt=(t2(n)-t2(n-1))/60; 
        end 
       [x,fval]= fzero(@(x)cytosolve(x,bigA,bigm,delt,S0),x0); % Send to solver 
        feval(n)=fval; 
        viab(n)=x; 
        rates(n)=(x-x0)/delt; 
        S0 = x; 
        x0 = x; 
    end 
viability=viab; 
rate=rates; 
B.7 Cytotoxicity Equation Solver 
function F = cytosolve(x,bigA,bigm,delt,S0) 
% Solve incremental equation where x = n/n0, bigA = (An-An-1)/2, A=b*C*exp(-d/T),  
% bigm = (mn-mn-1)/2, m = f*C and delt = tn-tn-1 so cytotoxicity eqn (from  
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